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ABSTRACT 
 
Epidemiological studies and molecular evidence assert that impaired 
glucose tolerance and cognitive decline could be associated, raising the 
possibility that these two conditions could have a common pathogenetic 
mechanism. 
PED/PEA-15 (Phosphoprotein Enriched in Diabetes/ Phosphoprotein 
enriched in astrocytes) is commonly overexpressed in individuals with type 2 
diabetes and its overexpression induces insulin-resistance both in vitro and in 
vivo. PED/PEA-15 is physiologically expressed at high levels in brain, and in 
particular its expression is enhanced in the hippocampus, prefrontal and frontal 
cortex, brain structures with an important role in learning and memory. 
By yeast two-hybrid screening, I identified APP (Amyloid Precursor 
Protein) and the α-secretase ADAM10 (A Disintegrin And Metalloprotease 10) 
as PED/PEA-15 molecular interactors in brain. Interestingly, both proteins are 
involved in the pathogenesis of Alzheimer’s Disease. I confirmed the 
interactions of PED/PEA-15 with APP and ADAM10 in intact cells and in 
mouse brain by co-immunoprecipitation and pull down experiments. In 
addition, I observed that APP co-precipitates with ADAM10 when PED/PEA-
15 is overexpressed, suggesting that PED/PEA-15 could act as a scaffold 
between these proteins. Then I evaluated the effect of PED/PEA-15 on APP 
proteolytic processing and I‘ve shown that in cells overexpressing APP, the 
transfection of PED/PEA-15: i) determines an increase of the release of soluble 
APP α fragment (sAPPα) in culture medium and of the membrane-bound 
fragment produced by α-secretase cleavage (CTF83), ii) reduces the plasma-
membrane expression of APP, iii) decreases the amount of β-amyloid peptide 
secreted in medium. Thus, it appears that PED/PEA-15 modulates APP 
proteolytic processing, promoting the α-pathway rather than the β-pathway. 
Inhibition of conventional PKC isoforms (cPKCs) by Bisindolylmaleimide 
(100nM) caused a dramatic reduction of PED/PEA-15- induced sAPPα release 
and reverted PED/PEA-15 effect on APP expression onto the plasma-
membrane. At variance, the ERK1/2 inhibitor PD98059 (50 µM) did not have 
any effect. Thus, data show that PED/PEA-15 promotes the physical contact 
between APP and ADAM10, inducing the α-proteolytic pathway. Moreover, 
PED/PEA-15 can regulate directly the α-secretase activity via a cPKCs-
dependent mechanism. 
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BACKGROUND 
 
The increase in life span in Western societies is accompanied with an 
increased incidence of age-related diseases including neurodegeneration and 
type 2 diabetes, that interfere with the quality of life and become a global issue. 
Currently, the prevalence of dementia within the population over the age of 65 
is about 10-15%. Moreover, it has been estimated that almost one half of the 
population over 85 will suffer dementia. According to the Global Burden of 
Disease Study (GBD), a collaborative study of the World Health Organization 
(WHO), the World Bank and the Harvard School of Public Health, dementia 
and other neurodegenerative diseases will be, in 2020, the eighth cause of 
disease burden for developed regions (Murray and Lopez 1996, Menken et al 
2000), while neurodegenerative diseases will become the world’s second 
leading cause of death by the middle of the century, overtaking cancer 
(Menken et al 2000). Diabetes is calculated to affect 5.9% of the world’s adult 
population (20-79 age group). Overall, the prevalence of diabetes is expected 
to increase worldwide from 246 million to 380 million people between 2007 
and 2025, representing 7.1% of the adult population (Diabetes Atlas 2006). It is 
known that approximately 20% of neurodegenerative disorders are associated 
with insulin-resistance and type 2 diabetes (Ristow 2004). 
Neurodegenerative diseases represent a varied assortment of central nervous 
system (CNS) disorders, inherited or sporadic, characterized by the gradual and 
progressive loss of specific subsets of neurons in specific functional anatomic 
systems. Although the causes may differ, patients with neurodegenerative 
disorders are likely to show localized to generalized atrophy of brain, leading 
to two principal phenotypic effects, not mutually exclusive: conditions causing 
problems with movements, such as ataxia, and conditions affecting memory. 
This compromising in mental and/or physical function dramatically reduces the 
quality of life for the patients, that, in the later stages of dementia, will lose the 
ability to care for oneself and will become dependent on other people, 
increasing the burden on the family and caregivers. 
 
 
§1. Classification of neurodegenerative diseases 
The number of neurodegenerative diseases is currently estimated to be a few 
hundred, and, among these, many appear to overlap with one another clinically 
and pathologically, rendering their practical classification quite challenging. 
The issue is further complicated by the fact that, in diseases such as multi-
system atrophy in which several areas of the brain are affected, different 
combinations of lesions can give rise to different clinical pictures (Burn and 
Jaros 2001). Furthermore, the same neurodegenerative process, especially at 
the beginning, can affect different areas of the brain, making a given disease 
appear very different from a symptomatic standpoint. Despite these difficulties, 
the most popular categorization of neurodegenerative disorders is still based on 
the predominant clinical feature or the topography of the predominant lesion, 
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or often on a combination of both. Indeed, clinical and pathological 
manifestations are determined by the location and seriousness of the disorder. 
Accordingly, neurodegenerative disorders of the CNS may, for example, be 
first grouped into diseases of the cerebral cortex, the basal ganglia, the 
brainstem and cerebellum, or the spinal cord. Then, within each group, a given 
disease may be further classified based on its main clinical features 
(Przedborski et al. 2003). 
Among the hundreds of different neurodegenerative disorders, the most 
prominent CNS disorders are Alzheimer’s Disease (AD), Parkinson’s Disease 
(PD), Huntington‘s Disease (HD) and amyotrophic lateral sclerosis (ALS) 
(Figure1). 
 
                                                                                                                  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        
 
Figure 1. Different populations of neurons are selectively vulnerable in different neurodegenerative 
disorders. In AD neurons in the hippocampus and certain regions of cerebral cortex degenerate; in PD, it is 
the dopaminergic neurons in the substantia nigra that undergo apoptosis; in HD, it is neurons in the striatum 
that die; and in ALS, spinal-cord motor neurons degenerate. 
 
 
§2. Protein aggregation and neurodegeneration 
With few exceptions, the mechanisms responsible of neurodegenerative 
diseases are essentially unknown, and even when they have been identified, the 
mechanisms by which they initiate the disease remain, at best, speculative. The 
possibility that protein aggregation plays a role in the pathogenesis of 
neurodegenerative diseases is a major focus of current research (Figure 2). 
Deposition of β-amyloid is strongly implicated in the pathogenesis of 
Alzheimer’s Disease. Mutations in genes encoding the microtubule-associated 
protein tau lead to altered splicing of tau and the production of neurofibrillary 
tangles in frontotemporal dementia. The characteristic histopathologic feature 
of Parkinson’s Disease is the Lewy body, an eosinophilic cytoplasmic 
inclusion that contains both neurofilaments and α-synuclein. Huntington’s 
Huntington‘s  
Disease  
Parkinson’s  
Disease 
Amyotrophic  
lateral sclerosis  
Alzheimer’s  
Disease  
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disease and cerebellar degenerations are associated with expansions of 
polyglutamine repeats in proteins, which aggregate to produce neuronal 
intranuclear inclusions. Familial ALS is associated with superoxide dismutase 
mutations and cytoplasmic inclusions containing superoxide dismutase. 
However, the precise causes of the abnormal accumulation of these proteins are 
not fully-understood. Increased synthesis and/or inability to degrade proteins 
could lead to protein aggregation inducing cellular dysfunction, impaired 
axonal transport, and cell death by apoptotic mechanisms. The current major 
scientific question is whether protein aggregates contribute to neuronal death or 
whether they are merely secondary bystanders (Harrison’s Principles of 
Internal Medicine 16th edition). 
 
                       
 
 
Figure 2. Protein aggregation as possible cause of neurodegenerative diseases. 
 
 
§3. Alzheimer’s Disease 
Alzheimer’s Disease (AD) is the most prevalent form of dementia (two third 
of cases of dementia) affecting more than 20 million people worldwide 
(Blennow et al. 2006, Pratico and Delanty 2000). AD has a prevalence of 
approximately 1% among those 65 to 69 years of age and increases with age to 
40 to 50% among persons 95 years of age and over (Nussbaum and Ellis 2003).  
The causes for the loss of brain functions are death of neurons and reduction 
of brain weight by more than 35%. This results in impaired memory, 
inattention, disoriented behavior, altered personality, problems with language, 
and impaired gait and movement. Diagnosis is based on neurological 
examination and the exclusion of other causes of dementia; a definitive 
diagnosis can be made only at autopsy (Nussbaum and Ellis 2003).  
The pathological hallmarks at the microscopic level are degeneration of the 
cholinergic neurons, neurofibrillary tangles (NTFs) and extracellular senile 
plaques containing the peptide β-amyloid (Nussbaum and Ellis 2003, Blennow 
2004) (Figure 3). 
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Figure 3. The microscopic pathological lesions of AD: intracellular neurofibrillary tangles and 
extracellular β-amyloid plaques.  
 
 
These features are found to be present in the temporal neocortex and 
hippocampal regions of the AD brain. The hippocampus resides in the cerebral 
cortex of the forebrain. It forms a part of the limbic system and plays a part in 
memory storage and spatial navigation (Newman et al. 2007) (Figure 4). 
                         
 
 
Figure 4. Major components of the Limbic System. 
 
 
NFTs are silver-staining, twisted neurofilaments in neuronal cytoplasm that 
represent abnormally phosphorylated tau protein and appear as paired helical 
filaments by electron microscopy. Tau is a microtubule-associated protein that 
may function to assemble and stabilize the microtubules that convey cell 
organelles, glycoproteins, and other important materials through the neuron. A 
hyperphosphorylated state of tau impairs its capacity to bind to microtubules 
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(Harrison’s Principles of Internal Medicine 16th edition). The amyloid plaque 
result from an aberration in deposition of β-amyloid (Aβ) peptide, a 4 kDa 
peptide of 40 to 43 amino acids derived from proteolytic cleavage of the 
amyloid precursor protein (APP), a membrane protein with unknown 
physiological function, by two enzymes, the β- and the γ- secretase. Soluble 
Aβ polymerizes to form oligomers, which fold to neurotoxic fibrils, and 
deposit around neurons (Figure 5). The exact mechanism by which Aβ peptide 
deposition induces neurotoxicity is unclear, but the accumulation of aggregated 
Aβ is hypothesized to initiate a pathological cascade resulting in the onset and 
progression of AD (Selkoe 1996, Newman et al. 2007).  
  
                
 
 
Figure 5. The amyloid cascade hypothesis. 
 
 
Familial forms of early-onset Alzheimer’s Disease (FAD), inherited in an 
autosomal dominant manner, are rare; indeed the most common form of AD in 
the population (approximately 90%) occurs sporadically and is late in onset, 
usually occurring after 65 years of age (Blennow et al. 2006, Pratico and 
Delanty 2000). However, the importance of FAD extends far beyond their 
frequency, because they have allowed researchers to identify some of the 
critical pathogenetic pathways of the disease. Three principal genes have been 
found to play important role in cases of FAD: gene encoding APP itself on 
chromosome 21, as well as in two genes with similarity to each other, 
presenilin 1 (PSEN1) on chromosome 14 and presenilin 2 (PSEN2) on 
chromosome 1. Mutations in APP itself or in the presenilins can shift the 
cleavage site to favor the γ-secretase site and, in particular, to favor increased 
production of the toxic Aβ42 peptide over the shorter, less toxic Aβ40 peptide 
(Nussbaum and Ellis 2003).  
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A discovery of great importance has implicated the Apoε gene on 
chromosome 19 in the pathogenesis of late-onset familial and sporadic forms 
of AD. Apoε is involved in cholesterol transport (Harrison’s Principles of 
Internal Medicine 16th edition) and has three alleles, designated 2, 3, and 4. The 
Apoε4 allele has a strong association with AD in the general population, 
including sporadic and late-onset familial cases. Approximately 40 to 65% of 
AD patients, compared to 24 to 30% of the nondemented Caucasian 
population, has at least one ε4 allele. Many AD patients have no ε4 allele, 
however, and individuals with ε4 may never develop AD. Nevertheless, it is 
clear that the Apoε4 allele, especially in the homozygous 4/4 state, is an 
important risk factor for AD (Harrison’s Principles of Internal Medicine 16th 
edition). The molecular mechanisms by which the various Apoε alleles alter 
the age at onset and, therefore, the lifetime risk of Alzheimer’s Disease are 
unknown. A number of associations of the disease with variants of genes other 
than Apoε have also been reported but remain to be confirmed and are the 
subject of ongoing research (Myers and Goate 2001). 
 
 
§4. Parkinson’s Disease 
Parkinson’s Disease is the second most common neurodegenerative 
disorder, after Alzheimer’s Disease. It has a prevalence of approximately 0.5 to 
1% among persons 65 to 69 years of age, rising to 1 to 3% among persons 80 
years of age and older (Nussbaum and Ellis 2003). It is characterized clinically 
by parkinsonism (resting tremor, bradykinesia, rigidity, and postural 
instability) and pathologically by the progressive loss of dopaminergic neurons 
in the substantia nigra and nigrostriatal pathway of the midbrain (Harrison’s 
Principles of Internal Medicine 16th edition). Microscopically there is 
degeneration of the dopaminergic cells with the presence of ubiquitinated 
protein deposits in the cytoplasm of the remaining neurons (Lewy bodies, LBs) 
and thread-like proteinaceous inclusions within neurites (Lewy neurites) 
(Harrison’s Principles of Internal Medicine 16th edition, Nussbaum and Ellis 
2003) LBs have a high concentration of α-synuclein and are the pathologic 
hallmark of the disorder. 
Although >90% of cases of idiopathic PD appear to be sporadic, increasing 
evidence indicates that genetic factors play an important role in many forms of 
PD. Familial clusters of autosomal dominant and recessive forms of PD 
comprise ~5% of cases (Table 1). These are characterized by an earlier age of 
onset (typically before age 50 years) and a longer course than the more typical 
“sporadic” PD. Four genes have been clearly linked to familial forms of PD 
(Table 1), and a number of other candidate genes or genetic loci have been 
identified as possibly causative of PD.  
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Table 1. Familial Parkinson’s Disease. AD= autosomal dominant; AR= autosomal recessive. (Harrison’s 
Principles of Internal Medicine, 16th edition) 
 
 
Among the former, PARK1 and PARK5 lead to an autosomal dominant 
form of PD with atypical features such as early age of onset and rapid 
progression of symptoms. PARK1 encodes α-synuclein, a predominantly 
neuronal protein with unknown function, leading to its abnormal aggregation. 
PARK2 and PARK7 lead to autosomal recessive disorders also with atypical 
features, including juvenile forms of parkinsonism. PARK2 encodes parkin, an 
E3 ubiquitin protein ligase. Mutations in parkin appear to be the major cause of 
autosomal recessive PD. Remarkably, PARK5 codes for the ubiquitin carboxy-
terminal hydroxylase L1 (UCH-L1), another component of the ubiquitin 
proteosomal system. Because ubiquitination of proteins targets them for 
degradation in the proteasome, these findings suggest that abnormal 
proteasomal processing is important in the pathogenesis of PD (Figure 6). 
Other mutations with yet-to-be identified genes include PARK10, a late-onset 
PD susceptibility gene. All these mutations are thought to affect α-synuclein or 
its biochemical processing, either directly or indirectly, but it is still unclear 
whether fibrils of aggregated a-synuclein, have a critical causative role in the 
more common forms of Parkinson’s Disease or are simply a marker for the 
underlying pathogenetic process (Harrison’s Principles of Internal Medicine 
16th edition). 
 14
            
 
Figure 6. Proteins and molecular pathways involved into the pathogenesis of PD. 
 
 
Recently the serin-protease Omi/HtrA2 has been associated with 
predisposition to PD. A homozygous loss of function mutation (S276C) in the 
Omi/HtrA2 gene was identified in mnd2 mice leading to neurodegeneration, 
muscle wasting and death by 40 days of age. The causative S276C mutation is 
located in the protease domain of Omi/HtrA2 and results in a loss of protease 
function possibly by impairing substrate access to the active binding site (Jones 
et al. 2003). The importance of the protease function of Omi/HtrA2 was 
recently underscored by the phenotypic characterization of Omi/HtrA2 
knockout mice. A complete lack of Omi/HtrA2 expression caused a 
neurodegenerative disorder with a parkinsonian phenotype including an 
akinetic-rigidic syndrome and tremor (Martins et al. 2004). Strauss et al. (2005) 
reported for the first time that mutations in the Omi/HtrA2 (G399S, A141S) 
gene are associated with a neurodegenerative disorder in humans. However, the 
mechanism through which the loss of Omi/HtrA2 activity determines 
neurodegeneration is unknown, but probably it involves a mitochondrial 
dysfunction (Jones et al. 2003, Martins et al. 2004). 
 
 
§5. Interaction between genes and environment in neurodegenerative 
diseases 
One of the most ferocious debates surrounding the etiology of 
neurodegenerative disorders concerns the relative roles of genetic and 
environmental factors in the initiation of these diseases. Some 
neurodegenerative disorders have a clear familial occurrence, suggesting a 
genetic basis. Among these affected families, the disease runs as an autosomal 
dominant trait, as in Huntington‘s disease. Less frequently, the disease runs as 
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an autosomal recessive trait, an X-linked trait, or even a maternally inherited 
trait. However, only a small minority of cases are of purely genetic origin. 
Most neurodegenerative disorders occur sporadically and they belong to the 
very long list of diseases that could arise through interactions among genetic 
and environmental factors. Parkinson’s Disease, for example, is considered a 
multifactorial disease resulting from the effect of environmental factors and 
genetic susceptibility. In addition to increasing age and male gender, risk 
factors for PD include head injury, exposure to pesticides, consumption of well 
water, and rural living (Harrison’s Principles of Internal Medicine 16th edition). 
No specific environmental risk factor was found to be consistently associated 
with Alzheimer’s Disease. Studies have reported associations of AD with 
depression, traumatic head injury, and cardiovascular-related disorders; 
however, it remains unclear whether these are true risk factors or simply co-
morbidities that increase severity of cognitive disorders (Przedborski S et al. 
2003). 
Recently, increasing evidence indicate that there is an association between 
impaired glucose tolerance, a common feature of several pathological 
conditions such as insulin-resistance, diabetes and metabolic syndrome, and 
neurodegenerative disorders. Impairment of insulin signaling in the brain has 
been linked to cognitive dysfunctions, but the extent and nature of the 
association have not been elucidated to date. 
 
 
§6. Association between neurodegenerative disorders, insulin-resistance 
and diabetes mellitus 
Many investigators have reported that approximately 20% of 
neurodegenerative disorders are associated with insulin-resistance and type 2 
diabetes. Compared to the overall incidence of diabetes mellitus in the general 
population of 4–8% (Zimmet et al. 2001), individuals suffering from 
neurodegenerative disorders exhibit a significantly higher prevalence of 
diabetes mellitus. For example, impaired glucose tolerance is frequently 
observed in Parkinson’s Disease and affects up to 80% of patients (Ristow 
2004). 
Several large, population-based studies in Europe and the United States 
suggest that impaired glucose tolerance and insulin resistant conditions, 
including diabetes and hyperinsulinemia, increase the risk for developing 
cognitive dysfunction. In the Kuopio study, investigators reported that older 
adults (mean age = 72.9 years) with persistent impaired glucose tolerance 
performed worse than did healthy older adults (mean age = 73.3 years) on the 
Mini-Mental State Examination and on long-term verbal memory from the 
Buschke Selective Reminding Test (Vanhanen et al. 1998, Watson and Craft 
2004). In the Honolulu–Asia Aging Study, type 2 diabetes was associated with 
an increased risk for incident dementia, incident Alzheimer’s Disease, and 
incident vascular dementia for a cohort of Japanese–American men who were 
followed for 3 years (Peila et al. 2002). In the Rotterdam and the Mayo studies, 
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type 2 diabetes increased the risk for Alzheimer’s Disease, independent of 
vascular dementia (Leibson et al. 1997, Ott et al. 1999, Watson and Craft 
2006). Conversely, Alzheimer’s Disease seems to predispose for insulin 
resistance (Razay and Wilcock 1994), insulin hypersecretion (Razay and 
Wilcock 1994), and type 2 diabetes mellitus (Janson et al. 2004). 
Peripheral and CNS insulin abnormalities have been reported in 
Alzheimer’s Disease patients. These patients have an increased risk for 
hyperinsulinemia and hyperglycemia, relative to healthy controls (Watson and 
Craft 2006). Patients with Alzheimer’s Disease, when compared with healthy 
controls, have lower cerebrospinal fluid (CSF) insulin levels, higher plasma 
insulin levels, and reduced insulin-mediated glucose disposal, a pattern 
consistent with insulin resistance (Craft et al 1999). Moreover, AD brains show 
reduced insulin receptor density and tyrosine kinase activity markers (Frolich 
et al. 1998). Collectively, these findings suggest that Alzheimer’s Disease may 
be associated with reduced insulin sensitivity and impaired insulin signaling 
(Messier 2003, Watson and Craft 2006). 
Thus, epidemiological studies and molecular evidence assert that insulin-
resistance and type 2 diabetes seem to be independent risk factors for 
Alzheimer’s Disease and other neurodegenerative diseases (European Journal 
of Pharmacology 2004, whole issue), suggesting that insulin-resistance can be 
involved in the development of cognitive disorders. 
 
 
§7. Insulin action 
Insulin is the most potent anabolic hormone known. It is involved in the 
control of tissue growth and development and in the regulation of glycidic, 
protein and lipid metabolism. Secreted by pancreatic beta cells in response to 
increase of plasmatic glucose and amino acids levels after feeding, insulin 
promotes the synthesis and storage of carbohydrates, lipids and proteins, while 
inhibiting their degradation and release into the circulation. Insulin stimulates 
the uptake of glucose, amino acids and fatty acids into cells, and increases the 
expression or activity of enzymes that catalyse glycogen, lipid and protein 
synthesis, while inhibiting the activity or expression of those that catalyse 
degradation. Insulin acts on three principal insulin-dependent target tissues, 
increasing glucose uptake in muscle and fat, and inhibiting hepatic glucose 
production (glycogenolysis and gluconeogenesis), thus serving as the primary 
regulator of blood glucose concentration (Saltiel and Kahn 2001). 
Until recently, the brain was described as an insulin insensitive organ; 
however, a growing body of evidence demonstrates that insulin participates in 
a number of normal and pathophysiological functions in the CNS (Watson and 
Craft 2004, Schwartz and Porte 2005, Watson and Craft 2006, Strachan 2003, 
European Journal of Pharmacology 2004, whole issue). Pancreatic insulin is 
transported across the blood-brain barrier (BBB) by a saturable, insulin 
receptor-mediated transport process (Baura et al. 1993, Banks et al. 1997a, 
Banks et al. 1997b). Acutely raising peripheral insulin levels also elevates 
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insulin levels in cerebrospinal fluid (Watson et al. 2003, Watson and Craft 
2006). Neuronal insulin synthesis has been demonstrated in animals (Rulifson 
et al. 2002, Devaskar et al. 1994, Watson and Craft 2006), and rats appear to 
express insulin genes in the hippocampus (Singh et al. 1997). However, insulin 
gene expression and synthesis is yet to be demonstrated in brain of mature 
adult humans. Insulin and insulin receptors are abundant but selectively 
distributed in the brain. Rodent studies have shown that insulin binding is 
highest in the olfactory bulb, cerebral cortex, hippocampus, hypothalamus, 
amygdala, and septum (Watson and Craft 2006). Insulin receptors are also 
expressed in the substantia nigra, basal ganglia, and frontal cortex (Watson and 
Craft 2006). In light of these distributions, insulin may contribute to selective 
brain functions such as the control of food intake, body weight and 
reproduction (Bruning et al. 2000, Schulingkamp et al. 2000, Watson and Craft 
2004). Insulin may influence cerebral glucose metabolism in specific brain 
regions. In the CNS, insulin-sensitive GLUT4 and GLUT8 transporters are 
selectively distributed. Rats express GLUT4 transporters in cerebellum, 
sensorimotor cortex, hippocampus, pituitary, and hypothalamus (Apelt et al. 
1999), and substantial co-localization has been reported for GLUT4 
transporters, insulin-containing neurons, and insulin receptors (Apelt et al. 
1999). Likewise, GLUT8 transporters are present in hippocampus and 
hypothalamus (Reagan et al. 2001). Therefore, overlapping distributions of 
insulin, insulin receptors, and insulin-sensitive GLUT isoforms constitute a 
platform for insulin-stimulated glucose uptake in selective brain regions, such 
as the hippocampus (Apelt et al. 1999). Insulin administration studies 
corroborate the notion that insulin contributes to normal memory functioning 
(Watson and Craft 2004). In rats, intracerebroventricular insulin administration 
enhances memory acutely on a passive-avoidance task, whereas control 
infusates (saline and heat-inactivated insulin) do not enhance memory (Park et 
al. 2000). In healthy older adults and adults with Alzheimer’s Disease, 
increasing plasma insulin levels (via intravenous insulin infusion) while 
maintaining euglycemia, facilitates recall of verbal declarative memory (i.e., 
story recall and word list recall) and enhances selective attention (Watson and 
Craft 2006). Moreover insulin seems to regulate the neurotransmitter release 
and the expression of neurotransmitter receptors, and so the synaptic plasticity. 
(Watson and Craft 2006). Thus, it is likely that insulin modulates learning and 
memory through diverse mechanisms including effects related to insulin 
signaling, cerebral glucose metabolism, neurotransmitter modulation (Watson 
and Craft 2004, Watson and Craft 2006). 
 
 
§8. Insulin-resistance and impaired glucose tolerance 
Once beta cells are stimulated by glucose, insulin is released in blood 
circulation and is distributed to all tissues. At this level, insulin acts on a 
specific receptor at high affinity, essential for insulin signaling transduction. 
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Alterations in insulin function are known as insulin-resistance (IR). Insulin 
resistance is defined as the condition in which normal amounts of circulating 
insulin are inadequate to produce a physiological insulin response from target 
cells. IR in fat cells results in hydrolysis of stored triglycerides, which elevates 
free fatty acids in the blood plasma; IR in muscle reduces glucose uptake, 
whereas IR in liver reduces glucose storage, with both effects serving to 
elevate blood glucose (Pickup and Williams 2005). Moreover, since brain 
could be considered an insulin-dependent tissue, it is possible to hypothesize 
the existence of cerebral insulin-resistance. High plasma levels of insulin and 
glucose due to insulin resistance often lead to metabolic syndrome and type 2 
diabetes. This is often seen when pancreatic β-cells are unable to produce 
adequate insulin to maintain normal blood sugar levels (euglycemia). The 
inability of the β-cells to produce more insulin in a condition of hyperglycemia 
is what characterizes the transition from insulin resistance to type 2 diabetes.  
Impaired Glucose Tolerance (IGT) is the name given to define blood 
glucose levels that are higher than normal, but below the level of a person with 
diabetes. In people with IGT, the rise in blood glucose that occurs after 
consuming 75g glucose is greater than normal, although not as great as in 
people with type 2 diabetes. Fasting blood glucose levels are normal or 
moderately raised. IGT is associated with insulin resistance and increased risk 
of cardiovascular pathology and it carries a high risk of progressing to type 2 
diabetes, leading to it being referred to as ‘pre-diabetes’. 
Alterations of components of insulin signal transduction are known 
mechanisms of IR (Figure 7). Synthesis of anomalous unfunctioning insulin is 
found in rare cases of IR. Genetic alterations of insulin receptor are the cause 
of severe insulin-resistance syndromes, such as leprecaunism, in which 
mutations of insulin receptor gene alter its expression or function. Then, 
several polymorphisms of Insulin Receptor Substrate 1 (IRS-1) and 
Phosphatidyl Inositol-3-Kinase (PI3K), proteins involved in insulin signaling, 
are linked to type 2 diabetes. Moreover, proteins involved in the regulation of 
insulin signaling could be associated to IR. For example, Phospho-Tyrosin-
Phosphatase-1B (PTP-1B) is a phosphotyrosine phosphatase that 
desphosphorylates insulin receptor and insulin receptor substrate, and it is 
responsible for the switching off of insulin signaling transduction. Its activity is 
increased in patients affected be type 2 diabetes (Saltiel and Kahn 2001).  
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Figure 7. Alterated components of insulin signaling in insulin-resistance. 
 
 
§9. The protein PED/PEA-15 
It has been recently discovered that the Phosphoprotein Enriched in 
Diabetes/ Phosphoprotein Enriched in Astrocytes-15 (PED/PEA-15) is 
overexpressed in fibroblasts, adipose and muscle tissue of type 2 diabetic 
patients compared to control individuals (Condorelli et al. 1998). Futhermore, a 
recent study showed that PED/PEA-15 overexpression represents a common 
abnormality in both type 2 diabetic patients and their First Degree Relatives 
(FDR)(Valentino et al. 2006) (Figure 8). PED/PEA-15 overexpression, both in 
vitro and in a transgenic mouse model (tgPED), induces insulin-resistance, 
impairs glucose tolerance and alters beta-cell function (Condorelli et al. 2001, 
Vigliotta et al. 2004, Miele et al.2007).    
      
 
 
 
 
 
 
 
 
 
     
Figure 8. Expression of PED/PEA-15 mRNA in human tissues. PED/PEA-15 is overexpressed in 
fibroblasts, adipose and muscle tissues and white blood cells of type 2 diabetes compared to control 
individuals. 
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PED/PEA-15 is a 15kDa cytosolic protein, originally identified as a major 
astrocyte phosphoprotein. It is widely expressed in different tissues and highly 
conserved among mammals, and its gene maps on human chromosome 1q21-
22 (Estelles et al. 1996). 
The structure of PED/PEA-15 includes a canonical N-terminal Death 
Effector Domain (DED) of 80 aminoacids that regulates apoptotic signaling 
pathways. Within the N-terminus PED/PEA-15 presents a Nuclear Export 
Sequence (NES) that mediates its predominantly cytoplasmic localization 
(Formstecher et al. 2001). At C-terminus, PED/PEA-15 presents two major 
phosphorylation sites, that regulate its stability (Figure 9). Indeed, PED/PEA-15 
is phosphorylated at Ser104 by protein kinase C (PKC) (Araujo et al. 1993, 
Estelles et al. 1996) and at Ser116 by calcium-calmodulin kinase II (CaMKII) 
and by Akt/PKB (Kubes et al. 1998, Trencia et al. 2003). 
 
 
 
 
Figure 9. Structure of PED/PEA-15. PED/PEA-15 protein presents at N-terminus the protein-protein 
domain DED and NES, that localizes the protein prevalently in the cytosol. The two major phosphorylation 
sites on Ser104 and Ser116 are visualized. 
 
 
PED/PEA-15 is physiologically expressed at high levels in brain, in 
particular in hippocampus, mammillary bodies, substantia nigra, frontal and 
prefrontal cortices as shown by Allen Brain Atlas (www.brain-map.org) and by 
our unpublished data of in situ hybridization experiments with an antisense 
probe complementary to PED/PEA-15 mRNA performed on rat brain sections 
(Figure 10).  
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Figure 10. PED/PEA-15 expression in cerebral areas. In situ hybridization experiments with an antisense 
probe complementary to PED/PEA-15 mRNA were performed on rat brain sections to evaluate PED/PEA-
15 expression in several cerebral regions. PED/PEA-15 is expressed at high levels in hippocampus and 
mammillary bodies. PED/PEA-15 levels are also elevated in pre-frontal and frontal cortices 
 
 
Several studies in cultured cells and in rodent tissues have revealed that 
PED/PEA-15 is a small scaffold multifunctional protein, that regulates multiple 
cellular functions by binding components of major intracellular transduction 
pathways (Zhang et al. 2000, Formstecher et al. 2001, Trencia et al. 2003, 
Vaidyanathan and Ramos 2003, Vigliotta et al. 2004).  
PED/PEA-15 controls mitogenic signaling by binding extracellular signal-
regulated kinases 1/2 (ERK1/2) and keeping them into the cytosol. 
(Formstecher et al. 2001). 
Several lines of evidence showed that PED/PEA-15 exerts an antiapoptotic 
action through different mechanisms. The DED of PED/PEA-15 binds the 
DED of both Fas Associated Death Domain (FADD) and caspase 8 (FLICE), 
thereby inhibiting FLICE activation by tumor necrosis factor-α and Fas-L, 
preventing DISC assembly and blocking the apoptotic effects of these 
cytokines (Condorelli et al. 1999). Interestingly, PED/PEA-15, also plays a 
crucial role in the negative regulation of TRAIL, a member of the TNF family 
that triggers rapid apoptosis in different types of tumor cells, included 
malignant glioma cells. Hao et al. (2001) have demonstrated that PED/PEA-15 
plays an important role in tumor sensitivity to anti neoplastic agents. Increased 
levels of protein confer greater susceptibility to skin carcinogenesis in vivo and 
may enhance cutaneous tumor progression toward malignancy (Formisano et 
al. 2005). Secondly, PED/PEA-15 prevents stress-activated protein kinase 
(SAPK) activation triggered by growth factor deprivation, oxidative stress 
(exposure to H2O2) and anisomycin treatment. This action of PED/PEA-15 is 
exerted by the blocking of an upstream event in the SAPK activation cascade 
and requires the interaction of PED/PEA-15 with ERK1/2. (Condorelli et al. 
2002). Thirdly, PED/PEA-15 modulates apoptosis upon UVC exposure in a 
dose-dependent fashion. After UVC exposure, mitochondrial serine-protease 
Omi/HtrA2 is released into the cytosol and binds and displaces the mammalian 
hippocampus 
mammillar bodies frontal cortex 
pre - frontal 
cortex 
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caspase inhibitor XIAP, releasing its suppressive effect on caspases activity. 
Interestingly, the mitochondrial release of Omi/HtrA2 is accompanied by a 
significant decrease in cellular PED/PEA-15 levels. Indeed, Omi/HtrA2 is able 
to interact with and to cleave PED/PEA-15 in the cytosol. Thus, at least in part, 
apoptosis following Omi/HtrA2 mitochondrial release is mediated by increased 
PED/PEA-15 degradation. By contrast, PED/PEA-15 overexpression blocks 
Omi/HtrA2-XIAP interaction thereby inhibiting the activation of the apoptotic 
pathway. Thus, the relative concentrations of Omi/HtrA2 and PED/PEA-15 
play an important role in committing the cells to apoptosis. (Trencia et al. 
2004). 
Recently PED/PEA-15 has been described to bind and to increase the 
stability of phospholipase D (Zhang et al. 2000), thus controlling important 
mechanisms in cell metabolism (Vigliotta et al. 2004, Condorelli et al. 2001). 
PED/PEA-15-induced resistance to insulin action on glucose disposal is 
accompanied by PLD-dependent activation of the classical protein kinase C 
isoform PKCalpha in muscle and adipose cells. In turn, PKCalpha induction 
prevents subsequent activation of the atypical PKCzeta by insulin. Rescue of 
PKCzeta activity in cells overexpressing PED/PEA-15 restores normal 
sensitivity to insulin of the glucose transport machinery (Condorelli et al. 
2001). Thus, in muscle and adipose cells, PED/PEA-15 generates resistance to 
insulin action on glucose disposal by impairing normal regulation of PKCzeta 
(Figure 11). Furthermore, in cultured muscle and adipose cells and in 
peripheral tissues from tgPED, high levels of PED/PEA-15 impair insulin-
stimulated GLUT4 translocation and glucose transport (Vigliotta et al. 2004, 
Condorelli et al. 2001). Characterization of tgPED mice evidenced that, in 
addition to generating insulin resistance and altered glucose tolerance, high 
levels of PED/PEA-15 also impair glucose-regulated insulin secretion. 
Moreover, tgPED mice become diabetic after administration of high-fat diets 
(Vigliotta et al. 2004). Thus, these findings identify PED/PEA-15 as a novel 
gene controlling insulin action and insulin secretion, contributing, under 
appropriate environmental conditions, to genetic susceptibility to type 2 
diabetes. 
   
                                      
Figure 11. Molecular mechanism of PED/PEA-15 action on insulin-stimulated glucose transport. 
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AIM OF THE STUDY 
 
In the last years increasing evidences indicate that there is an association 
between impaired glucose tolerance and cognitive decline. Indeed, alterations 
of genes involved in insulin signaling have also been found in patients with 
Alzheimer Disease (AD) and other neurodegenerative disorders (Watson and 
Craft 2006). Furthermore, epidemiologic studies indicate that patients with 
neurodegenerative disorders present an increased prevalence of insulin-
resistance or type 2 diabetes (T2D) compared to control individuals (Watson 
and Craft 2004, Watson and Craft 2006). This link suggests the possibility of a 
common pathogenetic mechanism for these conditions. 
PED/PEA-15 gene is overexpressed in tissue from type 2 diabetics 
(Condorelli et al. 1998, Valentino et al. 2006). PED/PEA-15 is involved in the 
regulation of insulin sensitivity and its overexpression causes insulin-
resistance in cultured cells and in transgenic mice (tgPED) (Vigliotta et al. 
2004, Miele et al.2007). 
PED/PEA-15 is physiologically expressed at high levels in brain, and in 
particular in hippocampus and in frontal and pre-frontal cortex, cerebral areas 
of limbic system. Nevertheless, its function in brain is still unclear.  
The aim of this work is to clarify PED/PEA-15 role in cerebral function and 
its possible involvement into pathogenesis of neurodegenerative diseases. 
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MATERIALS AND METHODS 
 
Yeast two Hybrid screening 
The yeast strain AH109, the mouse brain cDNA library in the pGADT7 
vector, and the Matchmaker Gal4 two-hybrid system 3 were from Clontech 
(CA). Generation of pGBKT7 yeast expression plasmids encoding the ped/pea-
15 full length cDNA was obtained by amplifying ped/pea-15, respectively, 
with the following set of primers: ped/pea-15 5’ NdeI (5’-
GGGAATTCCATATGGTTGAGTACGGG-3’) and 3’ped/pea-15 BamHI (5’-
CGCGGATCCTCAGGCCTTCTTCGCTGG GGGACC-3’). Plasmid DNA 
transformations were performed using a high efficiency lithium acetate 
procedure (Gietz et al. 1992). Cotransformants were propagated on Trp-, Leu- 
plates, and potential interacting clones selected in Trp-, Leu-, His-, Ade- media. 
After 4 days of incubation at 30 °C, positive clones were further tested for β 
galactosidase activity by liquid culture assays using the substrate o-
nitrophenyl-β-D-galactopyranoside as described in Experiments in Molecular 
Genetics (1972). Clones of interest were analyzed by DNA sequencing and 
BLAST analysis. 
 
 
Cell culture and transfection 
The HEK293 human kidney embryonic cells stably expressing ped/pea-15 
cDNA have been previously described (Condorelli et al. 2002); the N2a rat 
neuroblastoma cells stably expressing app cDNA were kindly provided by 
Prof. L. D’Adamio (Albert Einstein College of Medicine of Yeshiwa 
University, USA). The HEK293 and N2a cells were grown in Dulbecco’s 
modified Eagle’s medium supplemented with 10% fetal bovine serum, 100 
IU/ml penicillin, 100 IU/ml streptomycin, and 2% L-glutamine in a 5% 
humidified CO2 incubator. Transient transfection with RcCMV vector 
encoding app cDNA (kindly provided by Prof. N. Zambrano, DBBM of 
University of Naples “Federico II”, Italy) and pcDNA3 vector encoding 
ped/pea-15 cDNA (Condorelli et al. 1998) were performed using the 
Lipofectamine method according to the manufacturer’s instructions 
(Invitrogen, CA). Cells were also incubated for 24 hours with 
bisindolylmaleimide 100nM or PD98059 50µM. 
 
 
Western Blot analysis  
HEK293 were lysed in lysis buffer (50mM HEPES pH 7.6, 150mM NaCl, 
10mM EDTA, 10mM Na4P2O7, 2mM Na3VO4, 100mM NaF, 10% glycerol, 
1mM PMSF, 100 IU/ml aprotinin, 20µM leupetin, 1% Triton X-100) and N2a 
cells were lysed in 50mM Tris pH 7.4, 150mM NaCl, 2mM EDTA, 1% Triton 
X-100, 0.1% SDS, 1mM PMSF, for 2 h at 4 °C and lysates were centrifuged at 
14,000 x g for 15 minutes to remove cellular debris. Mouse brains were 
homogenized in a Polytron in T-PERTM extraction reagent (Pierce, IL) and 
 25
following manufacture’s instruction. Culture medium (100µl) was collected 
from cells 48 hours after transfection and was centrifuged for 10 min at 16,000 
x g to remove cellular debris. Tissues homogenates, cell lysates and media 
were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) and analyzed by western blot as previously described (Laemmli 
1970). Nitrocellulose membranes were probed with antibodies to PED/PEA-15 
(Condorelli et al. 1998), APP (clone 6E10; Sigma-Aldrich, MO), APP-C-term 
(Sigma-Aldrich, MO), sAPPα (IBL, Japan) ADAM10 (Stressgen, Canada). 
Immunoreactive bands were detected by enhanced chemiluminescence 
according to the manufacturer’s instructions (GE Healthcare, NJ). 
 
 
Co-immunoprecipitation 
 Lysates from HEK293 and Na2 transfected and untrasfected cells and 
mouse brains were incubated with pre-immune serum, PED/PEA-15 antibody 
or ADAM10 antibody (Santa Cruz Biotechnology, CA) at 4 °C for 16 hours. 
After incubation the mixture was incubated with protein A sepharose resin 
(Sigma-Aldrich, MO) pre-equilibrated with HNT buffer (50mM HEPES pH 
7.5, 150mM NaCl, 0,1 % Triton X-100) for 2 hours at 4 °C with vibrant 
shaking. The bound antibody-antigen complexes were washed three times with 
HNT and were then eluted in SDS sample buffer (Laemmli 1970). Total elute 
was separated by SDS-PAGE followed by immunoblotting with appropriate 
antibodies. 
 
 
Pull-down experiment 
 PED/PEA-15-glutatione S-transferase (GST) fusion protein was 
generated as described by Trencia et al. 2003. Cell lysates (500 µg of protein) 
were incubated in the presence of Sepharose-bound GST-PED/PEA-15 (5 µg) 
for 2 h at 4 °C. The beads were washed four times with HNT buffer and then 
resuspended in SDS sample buffer followed by boiling for 5 min and 
centrifugation at 25,000 x g for 3 min. Supernatants were separated by SDS-
PAGE followed by immunoblotting with appropriate antibodies. 
 
 
Cell surface Biotinylation 
To label cell surface molecules, cells were placed on ice and washed twice 
with PBS/Ca/Mg buffer (8mM Na2HPO4, 1,5mM KH2PO4, 2,7mM KCl, 
137mM NaCl, 0,1mM CaCl2, 1mM MgCl2, pH 7.4) and were then incubated in 
PBS/Ca/Mg buffer supplemented with 0.5 mg/ml EZ-LinkTM Sulfo-NHS-LC-
Biotin (Pierce, IL) for 30 min at 4 °C. Cells were then washed three times with 
PBS/Ca/Mg buffer plus 15mM glycine and were lysed in lysis buffer. 
Biotinylated cell surface proteins were immunoprecipitated with APP antibody, 
and immunoprecipitates were eluted by boiling in SDS sample buffer, 
electrophoresed on polyacrylamide gels, transferred to nitrocellulose, and 
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blotted with streptavidin-horseradish peroxidase conjugate (GE Healthcare, 
NJ). Blots were analyzed by enhanced chemiluminescence. 
 
 
Aβ ELISA 
Concentrations of secreted Aβ (1-42) produced by cells were analyzed in 
culture medium by ELISA colorimetric kit, as per the manufacturer's 
instructions (BioSource International, CA). 
 
 
Densitometric and statistical analysis 
 Densitometric analysis was performed using Scion Image Analyzer. Data 
were analyzed with Statview software (Abacus-concepts) by one-factor 
analysis of variance. p values of less than 0.05 were considered statistically 
significant. 
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RESULTS AND DISCUSSION 
 
Isolation and Identification of APP and ADAM10 as novel PED/PEA-15 
interacting proteins 
To clarify PED/PEA-15 role in the brain, I performed a yeast two hybrid 
screening to search for proteins that specifically interact with PED/PEA-15. To 
this aim, PED/PEA-15 protein fused to the DNA binding domain (DBD) of the 
yeast transcriptional factor Gal4 was used as bait; the screening was performed 
using a mouse brain cDNA library fused to the transcriptional activator domain 
(AD) of Gal4. Protein-protein interaction was identified firstly through the 
selection of positive clones on a selective medium without histidine and 
adenosine, then measuring the enzymatic activity of β-galattosidase. Based 
upon sequence analysis and BLAST searching, several potential interactors 
were identified: A Disintegrin And Metalloprotease 10 (ADAM10), Amyloid 
Precursor Protein (APP), Connexin32, GABA-A Receptor δ-subunit, 
Metallothionein 2A, and others. 
Among these positive clones, I have detained my attention on the proteins 
APP and ADAM10. APP is a single membrane-spanning protein possessing a 
large extracellular amino-terminal domain and a small cytoplasmic tail (Figure 
12). The APP gene is localized on chromosome 21 and it is ubiquitously 
expressed. Its pre-mRNA is alternatively spliced to produce three major protein 
isoforms APP770, APP751 and APP695; the last one is predominantly expressed 
in the brain. APP can be localized to many membranous structures in the cell 
such as the endoplasmic reticulum, Golgi compartments, secretory and 
endocytic vesicles as well as to the cell plasma-membrane. Interestingly, it has 
been detected in the membranes of synaptic and postsynaptic densities, axons 
and dendrites (Turner et al. 2003). The physiological function of APP is not yet 
completely clear. The protein seems to be involved in the phenomena of cell 
adhesion and migration, axon arborization, neuronal morphogenesis and 
formation of functional synapses (Gralle and Ferreira 2007, Turner et al. 2003). 
Instead, it is well known that APP is subjected to a physiological proteolytic 
processing by proteases collectively known as secretases that cut the protein in 
numerous secreted fragments with varying effects on neural function (Turner et 
al. 2003). Therefore, APP appears to play a significant role in regulating neural 
activity and plasticity both as a contact receptor and as a diffusible factor. From 
proteolytic processing of APP also origins the β-amyloid (Aβ) peptide, the 
principal proteinaceous component of senile plaques in brains of AD patients. 
Thus, APP is involved into the pathogenesis of Alzheimer’s Disease. 
On the other hand, the protein ADAM10 is a multi-function protein, 
belonging to a family of transmembrane glycoproteins (ADAMs family) that 
are characterized by several conserved distinct protein domains. These consist 
of an N-terminal propeptide domain, metalloprotease and disintegrin domains, 
a cysteine rich region, an epidermal growth factor (EGF)-like repeat, and 
finally a transmembrane domain and cytoplasmic tail (Lammich et al. 1999, 
Schlöndorff and Blobel 1999, Yang et al. 2006) (Figure 12). The propeptide 
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domain is removed by endopeptidases, called convertases, to activate the 
proteins. 
 
 
                                                                                                     
 
Figure 12. Schematic representations of structures of APP and ADAM10 proteins. Aβ= Amyloid β 
sequence; MP= metalloprotease domain; D= disintegrin domain; C= cysteine-rich domain; E= EGF repeat; 
TM= transmembrane domain 
 
 
Members of ADAM family have been implicated in several cell processes, 
including cell-cell adhesion and “ectodomain shedding”, a proteolytic process 
that affects cell surface molecules resulting in the release of soluble fragments 
(Lammich et al. 1999, Schlöndorff and Blobel 1999, Yang et al. 2006). In 
particular, the protein ADAM10 is involved in basal and stimulated shedding 
of APP. Indeed, it has been demonstrated that ADAM10 has an α-secretase 
activity, that promotes the non-amyloidogenic processing of APP (Lammich et 
al. 1999). 
Thus, it is interesting to notice that PED/PEA-15 could interact with two 
different proteins related to APP processing and AD pathogenesis.  
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APP and ADAM10 interact with PED/PEA-15 in vitro as well as in 
mammalian cells and mouse brain 
To verify the interaction of PED/PEA-15 with the two proteins identified by 
yeast two hybrid screening, I performed co-immunoprecipitation experiments 
(IP) in mammalian cells and pull-down assays (PD). HEK293 cells (Human 
Embryonic Kidney cell line) and rat neuroblastoma cells (N2a) were used 
because the first one are a simply transfectable cell line and N2a cells have a 
neuronal origin and so they constitute a more representative system. HEK293 
cells were stably transfected with ped/pea-15 cDNA (293PED) or with the 
empty vector (293pc), and transiently co-transfected with App. N2a cells stably 
overexpressing App (N2aAPP), were transiently transfected with the empty 
vector (pc) or with Ped/Pea-15. As shown in Figures 13a/13b, precipitation of 
lysates from the different cell types with PED/PEA-15 antibodies followed by 
blotting with APP antibodies revealed that PED/PEA-15 is able to bind APP 
and this interaction is more evident when PED/PEA-15 is overexpressed. Pre-
immune serum was used as control of specific immunoprecipitation. This 
interaction is also detectable in vitro by pull down experiments in N2a cells. 
Indeed, GST-fused recombinant PED/PEA-15 binds APP in N2a cell extracts 
and, more efficiently, in N2aAPP cells. Faint background signal was detectable 
using GST alone (Figure 13c). 
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Figure 13. Interaction of PED/PEA-15 with APP in HEK293 and neuroblastoma cells. a-b) HEK293 cells 
stably transfected with empty vector (293pc) or ped/pea-15 cDNA (293PED), transiently co-transfected with 
app cDNA, and N2aAPP cells transiently transfected with empty vector (pc) or ped/pea-15 cDNA (PED), 
were solubilized as described under Materials and Methods. Lysates were immunoprecipitated (IP) with 
PED/PEA-15 antibody (PED) or pre-immune serum (PI) followed by blotting with APP and PED/PEA-15 
antibodies. Total lysates were used as control of expression. c) N2a and N2aAPP cells were solubilized and 
lysates incubated for 2 h at 4 °C with Sepharose-GST-bound recombinant PED/PEA-15 (GST-PED) or GST 
alone, as indicated. Pulled down proteins and total cell extracts were then blotted with APP antibody as 
described under Materials and Methods. Blots were revealed by ECL and autoradiography. The shown 
autoradiographs are representative of four (a-b) and three (c) independent experiments. 
 
 
Similar IP and PD experiments were performed to demonstrate the 
association between PED/PEA-15 and ADAM10. As shown in Figure 14a, 
PED/PEA-15 interacts with both the active form of ADAM10 (64 kDa) and the 
90 kDa zymogen in 293PED cells and in N2a cells transfected with ped/pea-15 
cDNA. Co-precipitation was also detectable in control cells (N2a and 
HEK293), expressing only the endogenous compendium of the proteins. 
Interestingly, in cells overexpressing PED/PEA-15 an increase of levels of 
active form is appreciable, suggesting that PED/PEA-15 could regulate 
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ADAM10 activation or stability. The interaction has been confirmed by PD 
assays, which also indicate that interaction is more evident with the active form 
(Figure 14b). 
 
 
 
 
 
 
Figure 14. Interaction of PED/PEA-15 with ADAM-10 in HEK293 and N2a cells. a) 293 cells stably 
transfected with empty vector (293pc) or ped/pea-15 cDNA (293PED), and N2a transiently transfected with 
empty vector (N2a-pc) or ped/pea-15 cDNA (N2a-PED), were solubilized as described under Materials and 
Methods. Lysates were immunoprecipitated (IP) with PED/PEA-15 antibody (PED) followed by blotting with 
ADAM-10 and PED/PEA-15 antibodies. Total lysates were used as control of expression. b) N2a and 293 
cells were solubilized and lysates incubated for 2 h at 4 °C with Sepharose-GST-bound recombinant 
PED/PEA-15 (GST-PED) or GST alone, as indicated. Pulled down proteins and total cell extracts were then 
blotted with ADAM-10 antibody as described under Materials and Methods. Blots were revealed by ECL and 
autoradiography. The shown autoradiographs are representative of three (a-b) independent experiments. 
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To evaluate if the interactions between PED/PEA-15 and APP or ADAM10 
also occur in vivo, I performed IP experiments in brain extracts of PED/PEA-
15 transgenic mice (tgPED) and non transgenic littermates used as a control 
(wt). Not surprisingly both PED/PEA-15-APP and PED/PEA-15-ADAM10 
interactions are detectable in wt brain, since PED/PEA-15 expression levels are 
physiologically high in brain, but, as in cultured cells, the associations are more 
evident in tgPED brain (Figure 15). 
 
 
 
 
 
 
Figure 15. Interaction of PED/PEA-15 with APP and ADAM-10 in mouse brain. a-b) Brain from 
transgenic mice ubiquitously overexpressing PED/PEA-15 (tgPED) and from their not transgenic littermates 
(wt) were solubilized as described under Materials and Methods. Lysates were immunoprecipitated (IP) with 
PED/PEA-15 antibody (PED) followed by blotting with APP (a), ADAM-10 (b) and PED/PEA-15 (a) 
antibodies. Total lysates were used as control of expression. The shown autoradiographs are representative 
of three (a-b) independent experiments. 
 
 
These studies of protein-protein interaction confirm data obtained by yeast 
two hybrid screening: PED/PEA-15 associates the proteins APP and ADAM10, 
in vitro, in cells and in brain, suggesting a possible involvement of PED/PEA-
15 in the modulation of the activity and/or the function of these two proteins. 
 
 
Effect of PED/PEA-15 on APP-ADAM10 interaction 
Subsequently, I evaluated the association between APP and ADAM10 
proteins in N2a and N2aAPP cells, both transiently transfected with ped/pea-15 
cDNA or empty vector. Cells lysates were incubated with ADAM10 antibody 
and immunoprecipitates were blotted with APP antibody. As shown in Figure 
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16, ADAM10 is able to associate APP in N2aAPP cell extracts and PED/PEA-
15 overexpression increases this interaction, suggesting that PED/PEA-15 
promotes the formation of APP-ADAM10 complex, probably acting as a 
scaffold between these two proteins. Similarly, in N2a parental cells transient 
overexpression of PED/PEA-15 increased the immunodetection of APP in 
ADAM10 precipitation. 
 
 
Figure 16. Interaction of ADAM-10 with APP in N2a cells. a) N2a and N2aAPP cells transiently 
transfected with empty vector (pc) or ped/pea-15 cDNA (PED), were solubilized as described under 
Materials and Methods. Lysates were immunoprecipitated (IP) with ADAM-10 antibody followed by blotting 
with APP antibody. Blots were revealed by ECL and autoradiography. The shown autoradiographs are 
representative of three independent experiments. 
 
 
Effect of PED/PEA-15 on APP proteolytic processing  
As previously described, the proteolytic processing of APP by secretases is 
important for its physiological function as well as for its involvement in AD 
pathogenesis. Two main proteolytic cleavage sites close to the membrane and 
one site within the transmembrane domain have been identified and, starting  
from the amino terminus of the protein, are termed β, α and γ cleavage sites. 
Each cleavage is catalyzed by separate enzymes, referred to as β-, α- and γ-
secretases, respectively, that can act in several cellular compartments (Turner 
et al. 2003, Mills and Reiner 1999) (Figure 17). Two distinct proteolytic 
pathways origin from different combinations of cut: amyloidogenic pathway, 
from β/γ cleavage, and non-amyloidogenic pathway, from α/γ cleavage (Mills 
and Reiner 1999). 
                                     
 
Figure 17. Representation of cleavage sites on APP protein. 
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The β cleavage site occurs between residues 596 and 597 of APP695. This 
releases in extracellular space a fragment called soluble APP β (sAPPβ) and 
marks the N-terminus of the Aβ peptide in remaining C-terminal membrane-
anchored fragment (CTF99). Thus, β-secretase cut is the first prerequisite for 
generation of Aβ peptide. Indeed, CTF99 is subsequently processed by γ-
secretase to generate Aβ peptide. By contrast, APP is cleaved within the Aβ 
sequence by α-secretase between residues 16 and 17, resulting in the release of 
sAPPα fragment, that is 17 amino acids longer than sAPPβ, and precluding Aβ 
production. From C-terminal fragment (CTF83) γ-secretase action generates a 
3-kDa fragment, called p3, without amyloidogenic properties (Mills and Reiner 
1999, De Strooper and Annaert 2000) (Figure 18). 
        
 
 
Figure 18. Proteolytic processing of APP. 
 
 
To study the effect of PED/PEA-15 on APP proteolytic processing, I 
measured by Western Blot the amount of sAPPα released in culture medium of 
293pc and 293PED cells, transfected with app cDNA, and N2aAPP cells, 
overexpressing or not ped/pea-15 cDNA. Cells overexpressing PED/PEA-15 
release approximately two times and five times more sAPPα into the medium, 
respectively in HEK293 cells and in N2a cells, compared with untransfected 
cells, both in the presence and in the absence of serum (p<0.01) (Figure 19).  
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Figure 19. sAPPα secretion in culture media of 293+APP and N2aAPP cells. 293 cells stably 
transfected with empty vector (293pc) or ped/pea-15 cDNA (293PED), both transiently co-transfected with 
app cDNA, and N2aAPP transiently transfected with empty vector (pc) or ped/pea-15 cDNA (PED), were 
solubilized as described under Materials and Methods. Culture media were blotted with sAPPα antibody. 
Blots were revealed by ECL and autoradiography. The shown autoradiographs are representative of four 
independent experiments. sAPPα amount in culture media was expressed as densitometry levels (arbitrary 
unit) on protein concentration (µg/ml). Values are expressed as means ± SD. Asterisks denote statistically 
significant differences (***, p < 0.001). 
 
 
To confirm the effect of PED/PEA-15 on APP cleavage, APP plasma 
membrane (PM) expression was analyzed by biotinylation experiments in N2a 
and N2aAPP cells. When APP is overexpressed, it is present in large amount in 
plasma membrane; PED/PEA-15 overexpression strongly reduces the 
membrane expression of APP compared to the control (Figure 20). 
 
 
 
Figure 20. Plasma-membrane expression of APP in N2a and N2aAPP cells.  N2a and N2aAPP cells 
both transiently transfected with empty vector (pc) or ped/pea-15 cDNA (PED), were surface-biotinylated 
and solubilized as described under Materials and Methods. After immunoprecipitation with APP antibody 
and elution of the immuno-complexes, elutes and total lysates were blotted respectively with streptavidin-
horseradish peroxidase conjugate and with APP and PED/PEA-15 antibodies. Blots were revealed by ECL 
and autoradiography. The shown autoradiographs are representative of three independent experiments. 
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These data indicate that PED/PEA-15 alters APP proteolytic processing 
inducing an increase of sAPPα release. Considering that PED/PEA-15 interacts 
with the α-secretase ADAM10, it is plausible that PED/PEA-15 can modulate 
this activity. To gain further insight into PED/PEA-15 action on α-secretase 
pathway, I evaluated by Western Blot whether PED/PEA-15 expression also 
increases the level of CTF83, the membrane-bound fragment produced by α-
secretase cleavage. As shown in Figure 21, the expression of total cellular 
abundance of the full-length APP is not changed, whereas the signal for CTF83 
is stronger in N2aAPP cells overexpressing PED/PEA-15 than in control cells 
(p<0.05), further confirming that PED/PEA-15 increases α-secretase activity. 
 
 
Figure 21. CTF83 expression N2a cells. a-b) N2a cells and N2aAPP transiently transfected with empty 
vector (pc) or ped/pea-15 cDNA (PED), were solubilized as described under Materials and Methods. Total 
lysates were blotted with APP, CTF83 and PED/PEA-15 antibodies. a) Blots were revealed by ECL and 
autoradiography. The shown autoradiographs are representative of three independent experiments. b) 
CTF83 expression was expressed as CTF83 densitometry levels (arbitrary unit) on total APP densitometry 
levels. CTF83 levels in N2aAPP-PED is expressed as fold-increase over control (N2aAPP-pc).Values are 
expressed as means ± SD. Asterisks denote statistically significant differences (*, p < 0.05).  
 
 
To understand if PED/PEA-15 could also modulate β-processing of APP, I 
measured by ELISA the amount of Aβ peptide released into cultured medium 
of N2aAPP cells, transfected or not with PED/PEA-15. PED/PEA-15 
overexpression determines a 30% decrease of Aβ compared to control 
(N2aAPP: 30 ± 4 pg/ml vs. N2aAPP+PED/PEA-15: 21 ± 3 pg/ml; p<0.05) 
(Figure 22). 
Thus, these evidences indicate that PED/PEA-15 modulates APP proteolytic 
processing, promoting α-pathway rather than β-pathway and in this action 
could be involved ADAM10. 
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Figure 22. β-Amyloid secretion in N2aAPP cells. Culture media from N2aAPP cells transiently 
transfected with empty vector (pc) or ped/pea-15 cDNA (PED), were collected, and ELISA assay for β 
Amyloid quantization was performed as described under Materials and Methods. Values are expressed as 
means ± SD. Asterisks denote statistically significant differences (*, p < 0.05).  
 
 
The effect of PED/PEA-15 on APP processing is mediated by cPKCs 
The proteolytic processing of APP consists of a constitutive component and 
a regulated component. Previous studies have demonstrated an involvement of 
classical Protein Kinase C (cPKCs) and Mitogen Activated Protein Kinase 
(MAPKs) in both constitutive and regulated components (Mills and Reiner 
1999). Activation of PKC with phorbol esters (PMA) has been shown to 
strongly enhance the release of sAPPα and to inhibit the secretion of Aβ 
(Checler et al. 1995, Chen and Fernandez 2004). Moreover these effects are 
blocked by PKC inhibitors (Hung et al. 1993, Benussi et al. 1998) or by 
chronic pre-treatment with PMA, that down-regulates the kinase (Nitsch et al. 
1997). Also the MAPK cascade regulates sAPPα release (Mills and Reiner 
1999) and the exposure to PD98059, a selective inhibitor of MEK1 (Mitogen-
activated protein/ Extracellular signal-regulated protein Kinase 1) or 
overexpression of a kinase-inactive MEK mutant reduce MAPK effects on 
APP processing in a variety of a cell lines (Mills et al. 1997). The mechanism 
by which PKC and MAPK pathways modulate APP catabolism is unknown. It 
seems that it is not the APP itself that is phosphorylated, but that the substrate 
may be an α-secretase or some other molecules related with vesicle 
transportation that facilitate the increase of α-secretase activity (Mills et al. 
1997, Yang et al. 2007). As already cited in the introduction, it has been 
demonstrated that PED/PEA-15 is able to regulate ERK1/2 (Formstecher et al. 
2001) and PKCα activity (Zhang et al. 2000, Condorelli et al. 2001). To 
evaluate the possible involvement of these two kinases in PED/PEA-15 action 
on APP processing, N2aAPP cells, overexpressing or not ped/pea-15 cDNA, 
were treated with bisindolylmaleimide (BDM) 100nM or PD98059 50µM, 
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inhibitor respectively of cPKCs and MEK/ERK1/2. Inhibition of cPKCs by 
BDM caused a dramatic reduction of PED/PEA-15- induced sAPPα release. 
The treatment with PD98059 induced a decrease of sAPPα release both in 
PED/PEA-15 overexpressing cells and in control cells. However PED/PEA-15 
overexpression was still able to induce an increase of sAPPα secretion 
compared to the control. Concerning APP plasma membrane expression the 
BDM treatment reverted the effect of PED/PEA-15, while PD98059 had no 
effect (Figure 23). These data indicate that cPKC action could have a role in 
the effect of PED/PEA-15 overexpression on APP processing. It has to be 
clarified if α-secretase ADAM10 takes part in this mechanism. 
 
 
Figure 23. sAPPα secretion and plasma-membrane expression of APP in N2aAPP cells after 
treatment with BDM or PD98059. a-b) N2aAPP cells transiently transfected with empty vector (pc) or 
ped/pea-15 cDNA (PED), were incubated for 24h with 100 nM BDM or 50 µM PD98059. a)  Culture media 
were collected and blotted with sAPPα antibody. sAPPα amount in culture media was expressed as 
densitometry levels (arbitrary unit) on protein concentration (µg/ml). Values are expressed as means ± SD. 
Asterisks denote statistically significant differences (**, p < 0.01; ***, p < 0.001). b) Cells were surface-
biotinylated and solubilized as described under Materials and Methods. After immunoprecipitation with APP 
antibody and elution of the immuno-complexes, elutes were blotted with streptavidin-horseradish peroxidase 
conjugate antibody. Plasma-membrane expression of APP was expressed as densitometry levels (arbitrary 
unit). Values are expressed as means ± SD. Asterisks denote statistically significant differences (**, p < 
0.01; ***, p < 0.001). 
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CONCLUSIONS 
 
Phosphoprotein enriched in diabetes/phosphoprotein enriched in astrocytes 
(PED/PEA-15) is physiologically expressed at high levels in brain, in 
particular in hippocampus and in frontal and pre-frontal cortex. PED/PEA-15 
gene is overexpressed in tissues from type 2 diabetics and the protein is 
involved in the regulation of insulin sensitivity (Condorelli et al. 1998, 
Valentino et al. 2006). Indeed, its overexpression causes insulin-resistance in 
cultured cells and in transgenic mice (tgPED) (Condorelli et al. 2001, Vigliotta 
et al. 2004). Nowadays it is known that insulin-resistance and 
neurodegenerative diseases are associated and they could share common 
pathogenetic mechanisms. 
Based on these observations, I investigated the function of PED/PEA-15 in 
brain. I identified two new proteins able to interact with PED/PEA-15: APP 
(Amyloid Precursor Protein) and ADAM10 (A Disintegrin And 
Metalloprotease 10). Thus, PED/PEA-15 modulates APP proteolytic 
processing, promoting α-pathway rather than β-pathway and in this action 
could be involved the α-secretase ADAM10. The supposed model for 
molecular mechanism underlining PED/PEA-15 effect on APP proteolytic 
processing is the following: PED/PEA-15 promotes the formation of APP-
ADAM10 complex, probably acting as a scaffold between these two proteins. 
In this way PED/PEA-15 induces α-proteolytic pathway facilitating the 
physical contact between the enzyme and its substrate. Moreover, PED/PEA-
15 can directly regulate the α-secretase activity of ADAM10 activating cPKCs, 
which are known to phosphorylate and regulate the α-secretase (Mills et al. 
1997, Yang et al. 2007). 
It has been hypothesized that α-processing is protective for Alzheimer’s 
Disease, but it is not clear if an increase of α-cleavage and a conseguent 
accumulation of the α-fragment, or a decrease of the physiological levels of the 
β-amyloid fragment could be toxic for neuronal cells. Moreover, it might be 
also hypothesized that the increased processing of APP induced by PED/PEA-
15, and the concomitant decrease of APP plasma-membrane abundance, causes 
a loss of the physiological function of the full-length APP protein. Thus, it 
remains to clarify how PED/PEA-15-mediated modulation of APP processing 
can be involved in cognitive functions. 
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ped/pea-15 is a ubiquitously expressed 15-kDa pro-
tein featuring a broad anti-apoptotic function. In a
yeast two-hybrid screen, the pro-apoptotic Omi/HtrA2
mitochondrial serine protease was identified as a spe-
cific interactor of the ped/pea-15 death effector do-
main. Omi/HtrA2 also bound recombinant ped/pea-15
in vitro and co-precipitated with ped/pea-15 in 293 and
HeLa cell extracts. In these cells, the binding of Omi/
HtrA2 to ped/pea-15 was induced by UVC exposure and
followed the mitochondrial release of Omi/HtrA2 into
the cytoplasm. Upon UVC exposure, cellular ped/
pea-15 protein expression levels decreased. This effect
was prevented by the ucf-101 specific inhibitor of the
Omi/HtrA2 proteolytic activity, in a dose-dependent
fashion. In vitro incubation of ped/pea-15 with Omi/
HtrA2 resulted in ped/pea-15 degradation. In intact
cells, the inhibitory action of ped/pea-15 on UVC-in-
duced apoptosis progressively declined at increasing
Omi/HtrA2 expression. This further effect of Omi/
HtrA2 was also inhibited by ucf-101. In addition, ped/
pea-15 expression blocked Omi/HtrA2 co-precipitation
with the caspase inhibitor protein XIAP and caspase 3
activation. Thus, in part, apoptosis following Omi/
HtrA2 mitochondrial release is mediated by reduction
in ped/pea-15 cellular levels. The ability of Omi/HtrA2
to relieve XIAP inhibition on caspases is modulated by
the relative levels of Omi/HtrA2 and ped/pea-15.
Apoptosis is mediated by proteolytic activation of caspases.
Activated caspases catalytically degrade important intracellular
substrates and induce cell death (1, 2). The initial proteolytic
cleavage of caspases may be induced by the extrinsic cell-surface
pathway through the activation of the tumor necrosis family of
receptors, and/or by the intrinsic route through the release of
different apoptotic proteins from the mitochondria to the cyto-
plasm (3, 4). Because of its destructive nature, caspase activity
must be tightly regulated inside the cells. However, the identity
of the molecules involved in restraining apoptosis and their
mechanism of action have been only partially elucidated.
ped/pea-15 is a ubiquitously expressed cytosolic protein ex-
erting a broad anti-apoptotic action (5–10). First, by virtue of
its death effector domain (DED),1 ped/pea-15 binds other DED-
containing proteins, preventing formation of the death-induc-
ing signaling complex and inhibiting activation of the caspase
cascade (8). Indeed ped/pea-15 blocks apoptotic responses ini-
tiated by Fas ligand, tumor necrosis factor-, and tumor necro-
sis factor-related apoptosis-inducing ligand (7, 8, 10). Second,
ped/pea-15 inhibits p38 and JNK activation by stress-inducing
agents at a very upstream step in the stress-activated protein
kinase activation cascade (9). Thus ped/pea-15 exerts its anti-
apoptotic function by acting at multiple steps in the processes
leading to caspase activation. Whether ped/pea-15 also affects
apoptotic mechanisms triggered upon release of mitochondrial
proteins is unknown at the present.
The Omi/HtrA2 serine protease is an antagonist of the in-
hibitor of apoptosis proteins (IAPs) identified in mammals (11,
12). Omi/HtrA2 is a nuclear-encoded mitochondrial protein.
Cellular stresses, such as UV exposure, induces cleavage of the
Omi/HtrA2 mitochondrial localization sequence thereby gener-
ating a mature active molecule featuring a new apoptogenic
NH2 terminus, termed the IAP-binding motif (13). This motif
consists of a short stretch of hydrophobic amino acids. Hence,
Omi/HtrA2 is released into the cytosol and competitively binds
to the BIR domain of IAPs through the IAP-binding motif
(14–16). This event leads to the release and reactivation of the
BIR-bound caspases. Thus, Omi/HtrA2 binding displaces IAPs
from caspases releasing the suppressive effect on caspase ac-
tivity. Furthermore, Omi/HtrA2 can also trigger apoptosis in a
caspase-independent pathway, which entirely depends on its
serine protease function (17–20). However, neither the mecha-
nism nor the significance of this function is clearly understood.
In this article, we show that, upon release into the cytoplasm
of 293 cells, Omi/HtrA2 binds to and degrades ped/pea-15,
thereby removing its anti-apoptotic action and triggering apo-
ptosis. Thus, in addition to controlling the extrinsic pathway,
ped/pea-15 is also embedded into the intrinsic pathway induc-
ing caspase activation. We show that the relative levels of
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ped/pea-15 and Omi/HtrA2 play an important role in commit-
ting the cells to undergo apoptosis or survival.
EXPERIMENTAL PROCEDURES
Materials—Media, sera, and antibiotics for cell culture and the Li-
pofectAMINE reagent were from Invitrogen. PED polyclonal antibodies
have been previously described (6). Rabbit Omi/HtrA2 antisera were
raised by PRIMM (Milan, Italy), using the OVA-conjugated peptide
NH2-HRGEKKNSSSGISGSQRRY-COOH. Mouse monoclonal antibod-
ies toward XIAP were purchased from BD Biosciences and caspase 3
antibodies were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
The pcDNAIII vector encoding Omi/HtrA2 cDNA was a generous gift of
Dr. I. Iaccarino (Imperial Cancer Research Fund, London, UK), and was
reported by Martins et al. (20). The pGBKT7 yeast expression plasmids
encoding FADD and FLICE have been previously reported (21). The
yeast strain AH109, the human HeLa cDNA library in the pGADT7
vector, and the Matchmaker Gal4 two-hybrid system 3 were from Clon-
tech (Palo Alto, CA). Generation of pGBKT7 yeast expression plasmids
encoding the ped/pea-15 FL or DED cDNAs or the ped/pea-15-(80–130)
COOH terminus cDNA were obtained by amplifying ped/pea-15, respec-
tively, with the following sets of primers. ped/pea-15 5 NdeI (5-GG-
GAATTCCATATGGTTGAGTACGGG-3) and 3ped/pea-15 BamHI
(5CGCGGATCCTCAGGCCTTCTTCGCTGG GGGACC-3); ped/pea-15
5NdeI (5GGGAATTCCATATGGTTGAGTAC GGG-3) and ped/pea-15
3 EcoRI (5CCGGAATTCTCAAACCACCATAGTGAGTAGGTC-3);
ped/pea-15 5 EcoRI (5CCGGAATTCGACTACAGAA CCCGTGT-
GCTG-3) and ped/pea-15 3 BamHI (5CGCGGATCCTCAGGCCTTCT-
TCGCTGGGGGACC-3). SDS-PAGE reagents were purchase from Bio-
Rad. Radiochemicals, Western blotting, and ECL reagents were from
Amersham Biosciences. All other chemicals were from Sigma.
Cell Culture and Transfection, Cell Death, and Caspase 3 Cleavage
Assays—The 293 kidney embryonic cells stably expressing ped/pea-15
cDNA have been previously described (9). The 293 and HeLa cells were
grown in Dulbecco’s modified Eagle’s medium supplemented with 10%
fetal calf serum, 100 IU/ml penicillin, 100 IU/ml streptomycin, and 2%
L-glutamine in a humidified CO2 incubator. Transient transfection ex-
periments with Omi/HtrA2 and ped/pea-15 cDNAs were performed
using the LipofectAMINE method according to the manufacturer’s in-
structions (Invitrogen). Briefly, the cells were cultured in 60-mm dishes
up to 80% confluence and incubated for 24 h with the indicated amounts
of cDNA and 15 l of LipofectAMINE in serum-free Dulbecco’s modified
Eagle’s medium. An equal volume of Dulbecco’s modified Eagle’s me-
dium supplemented with 20% fetal calf serum was added for 5 h. The
medium was then replaced with Dulbecco’s modified Eagle’s medium
supplemented with 10% serum and the cells were further incubated for
24 h before the assay.
For detecting apoptosis, the cells were exposed to UVC (100 J/m2), as
indicated in the description of the individual experiments. Apoptosis
was then estimated using the Apoptosis ELISA Plus kit (Roche Diag-
nostics), according to the manufacturer’s instructions. For caspase 3
cleavage, subconfluent cells were exposed to UVC as above. The cells
were lysed in 1% Triton X-100, 150 mM NaCl, 10% glycerol, 20 mM
Tris-HCl, pH 7.5, 2 mM EDTA, 1 mM phenylmethylsulfonyl fluoride.
After centrifugation at 16,000 g for 15 min at 4 °C, supernatants were
subjected to Western blotting with caspase 3 antibodies.
Transformation of Yeast Strains and -Galactosidase Assay—Plas-
mid DNA transformations were performed using an high efficiency
lithium acetate procedure (22). Cotransformants were propagated on
Trp, Leu plates, and potential interacting clones selected in Trp,
Leu, His, Ade media. After 4 days of incubation at 30 °C, positive
clones were further tested for -galactosidase activity by liquid culture
assays using the substrate o-nitrophenyl--D-galactopyranoside as de-
scribed by Miller et al. (23). Clones of interest were analyzed by DNA
sequencing and BLAST analysis.
Cell Subfractionation and Western Blot Analysis—Subcellular frac-
tions were obtained as described in Refs. 24 and 25. Briefly, cells were
lysed in ice-cold 10 mM HEPES, pH 7.4, 5 mM MgCl2, 40 mM KCl, 1 mM
phenylmethylsulfonyl fluoride, 10 g/ml aprotinin, 10 g/ml leupeptin.
Lysed cells were centrifuged at 200  g to pellet nuclei. Supernatants
were centrifuged at 10,000  g to pellet the heavy membrane fraction
containing mitochondria, and the resulting liquid phase was further cen-
trifuged at 150,000 g to pellet plasmamembranes. The last supernatant
represented the cytosolic fraction (24). Mitochondria were further purified
by resuspending heavy membrane pellets in 250 mM mannitol, 0.5 mM
EGTA, 5 mM HEPES, pH 7.4, 0.1% bovine serum albumin, and layering
on 30% Percoll, 225 mM mannitol, 1 mM EGTA, 25 mM HEPES, pH 7.4,
0.1% bovine serum albumin. After centrifugation at 95,000 g, mitochon-
dria were recovered from the lower phase (26). Mitochondria were then
centrifuged, washed, and resuspended in 50mM potassium phosphate, pH
7.4, and used in the experiments described below. Purity of the mitochon-
drial fraction was assessed by assaying succinate dehydrogenase and
cytochrome c oxidase activities (27, 28). Results showed that 99% activ-
ity of these enzymes associated with the mitochondrial fractions and1%
of the total activities with the other fractions.
For Western blot assays, the cells were solubilized in lysis buffer
(50 mM HEPES, pH 7.5, 150 mM NaCl, 4 mM EDTA, 10 mM Na4PO7,
2 mM Na3VO4, 100 mM NaF, 10% glycerol, 1% Triton X-100, 1 mM
phenylmethylsulfonyl fluoride, 100 g/ml aprotinin, 1 mM leupeptin)
for 30 min at 4 °C. Lysates were centrifuged at 5,000  g for 15 min
and solubilized proteins were separated by SDS-PAGE and trans-
ferred on 0.45-m Immobilion-P membranes (Millipore, Bedford,
MA). Upon incubation with primary and secondary antibodies, im-
munoreactive bands were detected by ECL according to the manufac-
turer’s instructions.
In Vitro Interaction of Omi/HtrA2 and ped/pea-15 and Protease As-
say—To analyze ped/pea-15 interaction with Omi/HtrA2, a ped/pea-15-
glutatione S-transferase (GST) fusion protein was generated as de-
scribed in Ref. 29. Cell lysates (500 g of protein) were incubated in the
presence of Sepharose-bound GST-ped/pea-15 (2 g) for 2 h at 4 °C. The
beads were washed four times with TNT buffer (0.5% Nonidet P-40, 25
mM Tris, pH 7.5, 30 mM MgCl2, 40 mM NaCl, 1 mM dithiothreitol) and
then resuspended in Laemmli buffer followed by boiling for 4 min and
centrifugation at 25,000  g for 3 min. Supernatants were separated by
SDS-PAGE followed by blotting with Omi/HtrA2 antibodies.
Omi/HtrA2 protease activity was assayed by incubating 2 g of
recombinant his-Omi/HtrA2-(134–458) protein with 10 g of recombi-
nant ped/pea-15 in 20 mM HEPES, pH 7.4, 10 mM KCl, 1.5 mM MgCl2,
1 mM EDTA, 1 mM EGTA for 1 h at 37 °C. The reactions were stopped
with SDS-sample buffer and samples were boiled for 5 min. The reac-
tion products were analyzed be SDS-PAGE followed by Western blot
analysis using ped/pea-15 antibodies. Alternatively, the reaction prod-
ucts were resolved by SDS-PAGE followed by Coomassie Blue staining.
RESULTS
Isolation and Identification of Omi/HtrA2 as a Novel ped/
pea-15 Interacting Protein—To search for proteins that specif-
ically interact with ped/pea-15, a yeast two-hybrid system was
established using the full-length (FL) ped/pea-15 gene (pG-
BKT7-ped/pea-15) as bait to screen a human HeLa library
(Clontech). Upon HIS3 selection, 45 -galactosidase positive
cDNA clones were detected. Based upon sequence analysis and
BLAST searching, 6 of these clones were shown to match the
Omi/HtrA2 serine protease (11, 12, 30).
FIG. 1. Analysis of Omi/HtrA2 interaction with ped/pea-15
fragments. Measurement of the -galactosidase activity in trans-
formed yeasts is shown. The yeast reporter strain AH109 was co-
transformed with the pGADT7 plasmid encoding Omi/HtrA2 full-length
cDNA in combination with the pGBKT7 plasmid encoding the FL, DED,
or COOH terminus regions of ped/pea-15, or the DED of FADD or
FLICE. Transformants were isolated on selective plates. Activation of
the LacZ reporter gene was monitored by measuring -galactosidase
activity in cell lysates using o-nitrophenyl--D-galactopyranoside as
substrate. The activities are expressed in Miller’s units (23) and are the
average  S.D. of values obtained with samples prepared from five
independent transformants.
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We also sought to define the region responsible for the inter-
action of Omi/HtrA2 with ped/pea-15. We generated two fur-
ther pGBKT7 plasmids encoding either the DED (amino acids
1–80), or the COOH terminus region of ped/pea-15 (amino
acids 80–130). We then compared the ability of the pGADT7-
Omi/HtrA2 to interact with the full-length, DED, and the
COOH terminus regions of ped/pea-15 in the yeast system.
Measurement of -galactosidase activity revealed that Omi/
HtrA2 interacted with both the FL and ped/pea-15 DED fusion
proteins (Fig. 1). However, no Omi/HtrA2 interaction was de-
tected when the ped/pea-15 COOH terminus was used as bait.
No interaction was also detected when the DEDs of the FADD
or FLICE proteins were used, suggesting that Omi/HtrA2 spe-
cifically interacts with the ped/pea-15 death effector domain.
Omi/HtrA2 Interacts with ped/pea-15 in Vitro as Well as in
Mammalian Cells—Upon cell exposure to UV and other stress-
inducing agents, Omi/HtrA2 is released from mitochondria (18,
30) to the cytoplasm, where ped/pea-15 is largely localized (5,
31). To verify the interaction of Omi/HtrA2 with ped/pea-15 in
mammalian cells, we used HeLa cells expressing endogenous
ped/pea-15 and 293 cells stably transfected with ped/pea-15
cDNA (293PED). As shown in Fig. 2A, precipitation of lysates
from the two cell types with ped/pea-15 antibodies followed by
blotting with Omi/HtrA2 antibodies revealed little ped/pea-15
co-precipitation with Omi/HtrA2. UV exposure of the cells,
however, induced a 20-fold increase in the co-precipitation,
suggesting that UV-induced cleavage of Omi/HtrA2 is neces-
sary to enable interaction with ped/pea-15 as well as with IAPs.
Indeed, in control experiments, UV treatment caused the ap-
pearance of the 37,000 mature Omi/HtrA2 in the total cell
lysates and simultaneous disappearance of the 49,000 precur-
sor (data not shown). Whether in the absence or presence of UV
irradiation no co-precipitation occurred in untransfected 293
cells, as these cells do not express detectable levels of endoge-
nous ped/pea-15 (Fig. 2A).
Based on pull-down assays, GST-fused recombinant ped/
pea-15 bound to the endogenous Omi/HtrA2 in 293 cell extracts
(Fig. 2B). Omi/HtrA2 interaction with ped/pea-15 was 2-fold
more evident in lysates from 293 cells that have been tran-
siently transfected with the Omi/HtrA2 cDNA and overexpress
Omi/HtrA2 by 2.5-fold. No pull-down was detectable using GST
alone. No pull-down was detectable blotting with JNK rather
than with Omi/HtrA2 antibodies either, indicating that Omi/
HtrA2 specifically binds ped/pea-15 in vitro as well as in intact
mammalian cells.
Omi/HtrA2 Mitochondrial Release Is Accompanied by Re-
duced ped/pea-15 Cellular Levels—To further investigate the
biological significance of Omi/HtrA2 interaction with ped/pea-
15, we performed subcellular fractionation experiments in UV-
exposed and unexposed cells. In the absence of UV treatment,
Omi/HtrA2 was mainly mitochondrial both in the 293PED and
the ped/pea-15 untransfected cells (Fig. 3, A and B). In both cell
types, UV exposure led to an almost complete disappearance of
mitochondrial Omi/HtrA2 and a parallel appearance of Omi/
HtrA2 in the cytoplasmic fraction. At variance, ped/pea-15 was
only detected in the cytoplasm of the 293PED cells, whether
UV-treated or not. Indeed, co-precipitation of Omi/HtrA2 with
ped/pea-15 only occurred in the cytoplasmic fraction of the
293PED cells and only upon UV-induced mitochondrial release
(Fig. 3C). Importantly, upon UV exposure, ped/pea-15 cellular
levels declined in parallel with the release of Omi/HtrA2 into
the cytoplasm (Fig. 3B), raising the possibility that Omi/HtrA2
may reduce stability of ped/pea-15.
To test this hypothesis, we transiently overexpressed Omi/
HtrA2 in 293PED as well as in HeLa cells (expressing only
endogenous ped/pea-15). Then, upon UV light exposure, we
compared ped/pea-15 levels in the transfected versus the un-
FIG. 2. Interaction of Omi/HtrA2 with ped/pea-15 in HeLa and
293 cells and in vitro. A, HeLa cells expressing endogenous ped/
pea-15 and 293 cells, either expressing transfected ped/pea-15
(293ped/pea-15) or not, were exposed to UVC (100 J/m
2) and then solu-
bilized as described under “Experimental Procedures.” Lysates were
immunoprecipitated (IP) with ped/pea-15 antibodies followed by blot-
ting with Omi/HtrA2 antibodies. B, upon transient transfection with
Omi/HtrA2 cDNA, 293 cells were solubilized and lysates incubated for
2 h at 4 °C with Sepharose-GST-bound recombinant ped/pea-15 or GST
alone, as indicated. Pulled down proteins and total cell extracts were
then blotted with Omi/HtrA2 or JNK antibodies as described under
“Experimental Procedures.” Blots were revealed by ECL and autora-
diography. The autoradiographs shown are representative of four (A)
and three (B) independent experiments. WB, Western blot.
FIG. 3. Subcellular localization of Omi/HtrA2 and ped/pea-15. 293 cells stably overexpressing ped/pea-15 and control 293 cells were
exposed to UVC (100 J/m2) and cytosolic and mitochondrial fractions obtained as described under “Experimental Procedures.” 80 g of proteins
from each fraction were blotted with Omi/HtrA2 (A) or ped/pea-15 (B) antibodies or, precipitated with ped/pea-15 antibodies followed by blotting
with Omi/HtrA2 antibodies (C). Blots were revealed by ECL and autoradiography. The autoradiographs shown are representative of four (A and
B) and three (C) independent experiments. IP, immunoprecipitated; WB, Western blot.
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transfected cells. In both the 293PED and HeLa cells, overex-
pression of Omi/HtrA2 (20-fold above the endogenous levels)
caused only a slight 10% reduction in ped/pea-15 levels (Fig.
4A; p  0.01). However, upon UV irradiation and Omi/HtrA2
release into the cytoplasm, the cells overexpressing Omi/HtrA2
exhibited a 2-fold larger reduction in ped/pea-15 levels com-
pared with those expressing only the endogenous Omi/HtrA2.
Importantly, this decrease in ped/pea-15 levels was inhibited in
a dose-dependent fashion by the specific Omi/HtrA2 protease
inhibitor ucf-101 (Fig. 4B) (32), indicating that the UV effect is
largely dependent on Omi/HtrA2 protease activity.
We have therefore tested the hypothesis that ped/pea-15 may
serve as a direct Omi/HtrA2 substrate. We incubated recombi-
nant ped/pea-15 (rped/pea-15) with active recombinant Omi/
HtrA2-(134–458). After a 2-h incubation, we compared the
amount of intact ped/pea-15 remaining in the absence or pres-
ence of Omi/HtrA2. Based on Western blot analysis and Coo-
massie Blue staining (A), ped/pea-15 protein level was de-
creased by 60% in the presence of Omi/HtrA2 (Fig. 5). GST was
not affected by Omi/HtrA2, however (B). As shown in panel A,
Omi/HtrA2-induced disappearance of ped/pea-15 was pre-
vented by ucf-101, indicating specific cleavage of ped/pea-15 by
the Omi/HtrA2 protease in vitro.
Omi/HtrA2 Reduces ped/pea-15 Anti-apoptotic Function—
We also sought to examine the functional consequences of
Omi/HtrA2 mitochondrial release on ped/pea-15 function. To
this end, we analyzed UV-induced apoptosis in 293PED cells
upon transient transfection of increasing amounts of Omi/
HtrA2 cDNA. As shown in Fig. 6, the expression of ped/pea-15
in 293 cells was accompanied by a 90% reduction in UV apo-
ptosis. However, the anti-apoptotic function of ped/pea-15 was
reduced by Omi/HtrA2 transfection. This reduction paralleled
the increase in the Omi/HtrA2 expression level in the cells and
was prevented by ucf-101 treatment, suggesting that, in part,
apoptosis following Omi/HtrA2 mitochondrial release is medi-
ated by reduction in ped/pea-15 cellular levels. Indeed, in HeLa
cells, increased levels of transfected Omi/HtrA2 caused in-
creased degradation of endogenous ped/pea-15, which was in-
hibited by ucf-101 (Fig. 7A, top). As in the 293PED cells, Omi/
HtrA2 transfection in HeLa cells was accompanied by
augmented UV-induced apoptosis (Fig. 7A, bottom), as a func-
tion of the expression level of Omi/HtrA2 achieved (Fig. 7B).
If reducing the ped/pea-15 cytoplasmic level is relevant to
Omi/HtrA2 apoptosis in UV-exposed cells, one would also pre-
dict that increasing cellular levels of ped/pea-15 results in
limited Omi/HtrA2 function. To test this hypothesis, we fo-
FIG. 5. Effect of Omi/HtrA2 on ped/pea-15 in vitro. A, recombi-
nant ped/pea-15 (rped/pea-15; 10 mg) was incubated with the recombi-
nant Omi/HtrA2-(134–458) active fragment (rOmi/HtrA2-(134–458); 2
g) for 60 min at 37 °C. The reaction was stopped with Laemmli buffer
at 100 °C and proteins were separated by SDS-PAGE followed by blot-
ting with ped/pea-15 antibodies or Coomassie Blue staining. For con-
trol, GST was also incubated with rOmi/HtrA2-(134–458) as above,
followed by blotting with GST antibodies (B). Blots were revealed by
ECL and autoradiography. The images shown are representative of four
(A) and three (B) independent experiments.
FIG. 4. Effect of Omi/HtrA2 overexpression on ped/pea-15 levels. A, 293 cells stably expressing ped/pea-15 and HeLa cells were transiently
transfected with Omi/HtrA2 cDNA. The cells were then exposed to UVC (100 J/m2), solubilized, and then blotted with ped/pea-15 antibodies. For
control, aliquots of the lysates were also blotted with Omi/HtrA2 antibodies. Blots were revealed by ECL and autoradiography. The autoradio-
graphs shown are representative of four independent experiments. B, the 293ped/pea-15 cells were transiently transfected with Omi/HtrA2 and
exposed to UVC (100 J/m2) in the absence or presence of the indicated concentrations of ucf-101. The cells were then solubilized and blotted with
ped/pea-15 antibodies. Blots were reveled by ECL and autoradiography. The autoradiograph shown is representative of three independent
experiments. WB, Western blot.
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cused on UV-triggered apoptosis in 293 cells expressing in-
creasing amounts of ped/pea-15. In these cells, apoptosis pro-
gressively declined with increasing ped/pea-15 expression
levels (Fig. 8). Simultaneously, in 293PED as well as in HeLa
cells, ped/pea-15 overexpression inhibited Omi/HtrA2 co-pre-
cipitation with the caspase inhibitor protein XIAP (Fig. 9, A
and B). In HeLa cells, the effect of ped/pea-15 was accompanied
by an almost complete inhibition of UV-induced activation of
caspase 3 (Fig. 9C). Caspase 3 cleavage was well evident in
cells expressing only the endogenous ped/pea-15, however.
Similar results were obtained in 293 cells (data not shown).
Thus, in the cell, the ability of Omi/HtrA2 to release the XIAP
brake on caspase activation may be modulated by the relative
concentrations of Omi/HtrA2 and ped/pea-15.
DISCUSSION
Omi/HtrA2 is a nuclear-encoded mitochondrial serine prote-
ase serving as a sensor of unfolding stresses in the mitochon-
FIG. 6. Effect of Omi/HtrA2 on ped/
pea-15 function. 293 cells stably ex-
pressing either the control vector (pc) or
ped/pea-15 were transiently transfected
with 8 g of pcDNAIII (293ped/pea-15pc)
or the indicated amounts of Omi/HtrA2
cDNA and further incubated with 20 M
ucf-101 for 60 min, as indicated. The cells
were then exposed to UVC (100 J/m2) and
apoptosis was quantitated by the ELISA
Plus detection kit as described under “Ex-
perimental Procedures.” For control, ali-
quots of the samples were solubilized,
blotted with Omi/HtrA2 antibodies, and
revealed by ECL and autoradiography
(top panel). Bars represent the mean 
S.D. of duplicate determinations in four
independent experiments. The blot in the
top panel represents duplicate controls for
Omi/HtrA2 expression in UVC-treated
cells and are representative of three inde-
pendent experiments. WB, Western blot.
FIG. 7.Modulation of the anti-apop-
totic function of endogenous ped/
pea-15 by Omi/HtrA2 in HeLa cells. A,
HeLa cells were transiently transfected
with the indicated amounts of Omi/HtrA2
cDNA and further incubated with 20 M
ucf-101 for 60 min, as indicated. The cells
were then exposed to UVC (100 J/m2) and
apoptosis was quantitated by the ELISA
Plus detection kit as described under “Ex-
perimental Procedures.” Aliquots of the
samples were solubilized, blotted with
ped/pea-15 antibodies (top panel) or, for
control, with Omi/HtrA2 antibodies (B)
and revealed by ECL and autoradiogra-
phy (top panel). Bars represent the
mean  S.D. of duplicate determinations
in three independent experiments. WB,
Western blot.
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dria. In the mutant mnd2 mice, loss of the Omi/HtrA2 protease
activity leads to mitochondrial disintegration, neuronal degen-
eration, and death (33). It has been shown that, once in the
cytoplasm, Omi/HtrA2 promotes caspase activation and apo-
ptosis by binding to the BIR3 domain of the mammalian
caspase inhibitor XIAP (13, 30).
Omi/HtrA2 binding displaces XIAP from caspases, inhibiting
the suppressive effect on caspase activity (13–16). There is also
evidence that interaction with IAPs is not the only mechanism
involved in Omi/HtrA2-induced cell death, as the serine prote-
ase activity of Omi/HtrA2, when localized in the cytosol, is
sufficient to cause caspase-independent cell death (17). This
evidence led to the concept that protease activity plays an
important role in regulation of apoptosis by Omi/HtrA2 (32).
Indeed, Srinivasula et al. (34) have shown that IAPs are sub-
strates for Omi/HtrA2 and their degradation may contribute to
caspase activation by Omi/HtrA2. However, whether other sub-
strates also play a role in Omi/HtrA2-induced cell death
is unknown.
In the present work, we have identified the serine protease
Omi/HtrA2 as a novel ped/pea-15 interactor, by yeast two-
hybrid screening. Furthermore, we show that the anti-apo-
ptotic protein ped/pea-15 co-precipitates with Omi/HtrA2 in
mammalian cell extracts and specifically binds Omi/HtrA2 in
pull-down assays. Thus, Omi/HtrA2 may also bind ped/pea-15
in mammalian cells. At variance with ERK, another ped/pea-
15-binding protein (35), Omi/HtrA2 interaction requires the
DED of ped/pea-15. Indeed, a truncated protein, lacking the
entire DED, does not interact with Omi/HtrA2 in yeast. Fur-
thermore, the DED of ped/pea-15 but not that of other DED-
containing proteins, is sufficient for the interaction to occur,
indicating specificity of Omi/HtrA2 for the DED of ped/pea-15.
Interestingly, the mitochondrial release of Omi/HtrA2 in
response to UV exposure was accompanied by a significant
decrease in cellular ped/pea-15 levels. This effect was amplified
upon overexpression of Omi/HtrA2 cDNA and might have been
produced either by Omi/HtrA2 decreasing ped/pea-15 synthesis
FIG. 9. Effect of ped/pea-15 on Omi/HtrA2 co-precipitation
with XIAP and caspase 3 activation. A, 293 cells were transiently
transfected with the indicated amounts of ped/pea-15 cDNA and then
exposed to UVC (100 J/m2). The cells were solubilized and precipitated
with XIAP antibodies, followed by blotting with Omi/HtrA2 antibodies.
For control, aliquots of the cell lysates were also blotted with ped/pea-15
or XIAP antibodies, as indicated. B and C, HeLa cells were transfected
with ped/pea-15 cDNA or with a control plasmid. Aliquots of the lysates
obtained from unexposed or UVC-exposed cells were either precipitated
with XIAP antibodies, followed by blotting with Omi/HtrA2 antibodies
(B, top panel) or directly blotted with ped/pea-15 (B, middle panel),
XIAP (B, bottom panel), and caspase 3 antibodies (C). Blots were re-
vealed by ECL and autoradiography. The autoradiographs shown are
representative of three independent experiments. WB, Western blot.
FIG. 8. Effect of ped/pea-15 on Omi/HtrA2 function. 293 cells were transiently transfected with either the control plasmid (293pc) or
Omi/HtrA2 cDNA. Co-transfection with the indicated amounts of ped/pea-15 cDNA was also achieved. The cells were then exposed to UVC (100
J/m2) and apoptosis was quantitated by the ELISA Plus detection kit as described under “Experimental Procedures.” For control, aliquots of the
samples were solubilized, blotted with ped/pea-15 antibodies, and revealed by ECL and autoradiography (top panel). Bars represent the mean 
S.D. of duplicate determinations in four independent experiments. The blots shown are representative of those obtained in the four experiments.
WB, Western blot.
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and/or by increasing its degradation. The latter appeared a
more likely possibility based upon the information that Omi/
HtrA2 features serine-protease activity (11, 18–20). Consis-
tently, we have shown that, (i) ped/pea-15 is a substrate of
Omi/HtrA2 serine protease in vitro; and (ii) the reduction in
ped/pea-15 levels accompanying UV-induced release of Omi/
HtrA2 frommitochondria is blocked by a specific inhibitor of its
serine protease activity. Thus, the evidence indicates that,
upon being released into the cytoplasm, Omi/HtrA2 binds to
and degrades ped/pea-15.
Degradation of ped/pea-15 by Omi/HtrA2 was accompanied
by reduction of the ped/pea-15 apoptosis-inhibiting function.
Indeed, the protection from UV-induced apoptosis accom-
plished by ped/pea-15 in both HeLa and 293 cells was progres-
sively abolished by increasing the expression levels of Omi/
HtrA2 in the cell, and this effect was blocked by inhibition of
the Omi/HtrA2 serine protease. We suggest therefore that, in
part, the caspase-independent cell death induced by cytoplas-
mic release of Omi/HtrA2 is mediated by ped/pea-15 degrada-
tion. The relevance of ped/pea-15 to Omi/HtrA2 apoptosis was
further underlined by the finding that, in 293 cells, the ability
of Omi/HtrA2 to bind XIAP and induce cleavage and activation
of caspase 3 progressively declined in close parallel with in-
creasing ped/pea-15 cellular levels and with increasing protec-
tion from UV-induced apoptosis. Thus, the relative concentra-
tions of Omi/HtrA2 and ped/pea-15 in the 293 cell cytoplasm
play an important role in committing the cells to apoptosis.
Compartmentalization appears to be a major mechanism
through which control of this balance is accomplished in the
293 cells. Indeed, in the present work, we show that Omi/HtrA2
interaction with ped/pea-15 only occurs in the cytoplasm and
upon UV-induced release of Omi/HtrA2 from the mitochondria.
Apoptotic signals alter Omi/HtrA2 compartmentalization ena-
bling its protease activity toward different cytoplasmic sub-
strates whose cleavage fosters activation of the apoptotic ma-
chinery of the cell.
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Phorbol Esters Induce Intracellular Accumulation of the
Anti-apoptotic Protein PED/PEA-15 by Preventing
Ubiquitinylation and Proteasomal Degradation*
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Phosphoprotein enriched in diabetes/phosphoprotein en-
riched in astrocytes (PED/PEA)-15 is an anti-apoptotic protein
whose expression is increased in several cancer cells and follow-
ing experimental skin carcinogenesis. Exposure of untrans-
fected C5N keratinocytes and transfected HEK293 cells to
phorbol esters (12-O-tetradecanoylphorbol-13-acetate (TPA))
increased PED/PEA-15 cellular content and enhanced its
phosphorylation at serine 116 in a time-dependent fashion.
Ser-116 3 Gly (PEDS116G) but not Ser-1043 Gly (PEDS104G)
substitution almost completely abolished TPA regulation of
PED/PEA-15 expression. TPA effect was also prevented by anti-
sense inhibition of protein kinase C (PKC)- and by the expres-
sion of a dominant-negative PKC- mutant cDNA in HEK293
cells. Similar to long term TPA treatment, overexpression of
wild-type PKC- increased cellular content and phosphoryla-
tion of WT-PED/PEA-15 and PEDS104G but not of PEDS116G.
These events were accompanied by the activation of Ca2-cal-
modulin kinase (CaMK) II and prevented by the CaMK blocker,
KN-93. At variance, the proteasome inhibitor lactacystin mim-
icked TPA action on PED/PEA-15 intracellular accumulation
and reverted the effects of PKC- and CaMK inhibition. More-
over, we show that PED/PEA-15 bound ubiquitin in intact cells.
PED/PEA-15 ubiquitinylation was reduced by TPA and PKC-
overexpression and increased by KN-93 and PKC- block. Fur-
thermore, in HEK293 cells expressing PEDS116G, TPA failed to
prevent ubiquitin-dependent degradation of the protein.
Accordingly, in the same cells, TPA-mediated protection from
apoptosis was blunted. Taken together, our results indicate that
TPA increasesPED/PEA-15 expression at thepost-translational
level by inducing phosphorylation at serine 116 and preventing
ubiquitinylation and proteosomal degradation.
Cancer cells feature both excessive proliferation and aban-
donment of the ability to die (1, 2). Thus, alterations of genes
involved in the control of apoptosis have been implicated in a
number of human malignancies. In certain lymphomas, for
example, cell death is blocked by excessive production of the
anti-apoptotic factor Bcl-2 (2). Similarly, some tumors prevent
apoptosis by up-regulating the expression of anti-apoptotic
death effector domain (DED)2-containing proteins, which, in
turn, inhibit Fas from conveying signals to the deathmachinery
(3).
Phosphoprotein enriched in diabetes/phosphoprotein
enriched in astrocytes (PED/PEA)-15 is a DED-containing pro-
tein originally identified in astrocytes as a protein kinase C
(PKC) substrate (4–6) and found overexpressed in insulin tar-
get tissues of patients with type 2 diabetes (7). Raised PED/
PEA-15 levels have also been detected in several human tumor
cell lines (7–9). A growing body of evidence indicates that
increased PED/PEA-15 expression may provide a mechanism
to escape cell death upon a number of pro-apoptotic stimuli
(10–14).Moreover, in transgenicmice, overexpression of PED/
PEA-15 enhances the susceptibility to develop experimentally
induced skin tumors (15). The molecular mechanism of PED/
PEA-15 anti-apoptotic action has been extensively investi-
gated. In several cell types, PED/PEA-15 blocks Fas- and tumor
necrosis factor--induced apoptosis by competing with its
DEDwith the interaction between FADD and caspase 8 (10). In
addition, in several cell lines of human glioma, PED/PEA-15
inhibits tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL)-induced apoptosis, thereby generating resist-
ance to this anti-neoplastic agent (9). At variance with other
anti-apoptotic proteins inhibiting caspase 8 activation via
FADD trapping (3), PED/PEA-15 overexpression also prevents
apoptosis induced by growth factors deprivation, UV exposure,
and osmotic stimuli (11, 13).
Besides the anti-apoptotic function, a role for PED/PEA-15
in restraining cell proliferation has been proposed (16–20). It
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protein kinase C; CaMK, calmodulin kinase; FADD, Fas-associated death
domain; HA, hemagglutinin; DMEM, Dulbecco’smodified Eagle’smedium;
RT, reverse transcription; PBS, phosphate-buffered saline; Ab, antibody;
ASO, antisense oligonucleotides; DN, dominant-negative; WT, wild type;
SO, scrambled.
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has been described that PED/PEA-15 directly binds extracellu-
lar signal-regulated kinase 2 (ERK2) and RSK2 and prevents
their nuclear translocation and transduction of biological
effects (16–19). Together with the anti-apoptotic effect, this
action may expand cellular senescence (20).
PED/PEA-15 is a phosphorylated protein (4, 5). It has
recently been shown that PED/PEA-15 phosphorylation at spe-
cific sites controls the ability of the protein to form complexes
with specific intracellular interactors (21). PED/PEA-15 serine
phosphorylation has also been shown to enhance protein sta-
bility (22). Several kinases were evidenced to phosphorylate
PED/PEA-15 at specific serines. Ser-104 represents the main
target for PKC phosphorylation (4, 5, 23), whereas Ser-116 has
been shown to be a target site for both Ca2-calmodulin kinase
(CaMK) II (23) and protein kinase B (PKB)/Akt (22). However,
the precise function of these phosphorylation sites in control-
ling PED/PEA-15 expression is currently unknown. Recent evi-
dence indicates that abnormal accumulation of PED/PEA-15may
lead to derangement of cell growth andmetabolism (15, 24, 25).
In this study, we have shown that phorbol esters, which are
tumor promoters and inhibitors of insulin action, up-regulate
PED/PEA-15 expression by inhibiting its ubiquitinylation and
proteasomal targeting. This effect involves activation of
CaMKII and subsequent phosphorylation of PED/PEA-15 at
Ser-116. PKC- activity is required for phorbol ester-induced
activation of CaMKII and for the regulation of PED/PEA-15
degradation.
EXPERIMENTAL PROCEDURES
Materials—Media, sera, and antibiotics for cell culture and
the Lipofectamine reagent were purchased from Invitrogen
(Paisley, UK). Rabbit polyclonal PKC-, PKC-, PKC-, PKC-,
and phospho-PKC antibodies were from Santa Cruz Biotech-
nology (Santa Cruz, CA). PED/PEA-15, p-Ser-104PED, and
p-Ser-116PEDand antibodies have been previously reported (7,
22). Mouse monoclonal polyubiquitinylated protein antibodies
(FK1) were from Biomol International. Mouse monoclonal HA
antibody were from Roche Applied Science. Phosphorothioate
PKC-, PKC-, PKC-, PKC- antisense and scrambled con-
trol oligonucleotides have been previously described (26–28)
and were synthesized by PRIMM (Milan, Italy). PKC- wild-
type and dominant-negative constructs were kindly provided
byDr.M. S.Marber (St. ThomasHospital, London,UK) andDr.
S.Gutkind (NCI, National Institutes of Health, Bethesda, MD),
respectively. SDS-PAGE reagents were purchased from Bio-
Rad. Western blotting and ECL reagents and radiochemicals
were from Amersham Biosciences. All other reagents were
from Sigma.
Plasmid Preparation, Cell Culture, and Transfection—The
PEDS104G andPEDS116Gmutant cDNAswere prepared by using
pcDNAIIIPEDY1 cDNA (pcDNAIII containing His6-Myc-
tagged PED/PEA-15) as template with the site-directed
mutagenesis kit by Promega according to the manufacturer’s
instructions. Stable expression of the mutants and wild-type
PEDY1 cDNAs in HEK293 cells (293PEDY1) was achieved as
reported in Condorelli et al. (11). The cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% fetal calf serum, 100 IU of penicillin/ml, 100 IU of
streptomycin/ml, and 2% L-glutamine in a humidified CO2
incubator. Transient transfection of phosphorothioate oligo-
nucleotides and plasmid DNA in HEK293 cells was accom-
plished by using the Lipofectamine method according to the
manufacturer’s instructions. Briefly, the cells were cultured in
60-mm-diameter dishes and incubated for 24 h in serum-free
DMEM supplemented with 3 g of cDNA and 15 l of Lipo-
fectamine reagent. An equal volume of DMEM supplemented
with 20% fetal calf serum was then added for 5 h followed by
replacement with DMEM supplemented with 10% serum for
24 h before the assays.
Western Blot Analysis—ForWestern blotting, cells were sol-
ubilized in lysis buffer (50mMHEPES (pH 7.5), 150mMNaCl, 4
mM EDTA, 10 mM Na4PO7, 2 mM Na3VO4, 100 mM NaF, 10%
glycerol, 1%TritonX-100, 1mMphenylmethylsulfonyl fluoride,
100mg of aprotinin/ml, 1mM leupeptin) for 60min at 4 °C. Cell
lysates were clarified at 5,000  g for 15 min. Solubilized pro-
teins were then separated by SDS-PAGE and transferred onto
0.45-m-pore size Immobilon-P membranes (Millipore, Bed-
ford, MA). Upon incubation with the primary (PED, etc.) anti-
body and secondary antibodies, immunoreactive bands were
detected by ECL according to the manufacturer’s instructions.
Real-time RT-PCR Analysis—Total cellular RNA was iso-
lated from C5N cells by the use of RNeasy kit (Qiagen) accord-
ing to the manufacturer’s instructions. For real-time RT-
PCR analysis, 1 g of cell RNA was reverse-transcribed using
SuperScript II reverse transcriptase (Invitrogen). PCR reaction
mixes were analyzed using SYBRGreenmix (Invitrogen). Reac-
tions were performed using Platinum SYBRGreen quantitative
PCR Super-UDG using an iCycler IQmulticolor real-time PCR
detection system (Bio-Rad). All reactions were performed in
triplicate, and -actin was used as an internal standard. Primer
sequences used were as follows: PED/PEA-15, forward, 5-
TTCCCGCTGTTCCCTTAGG-3, and PED/PEA-15, reverse
5-TCTGGCTCATCCGCATCC-3.
Immunoprecipitation of PED/PEA-15—Cells grown in
100-mmPetri disheswere treated as indicated andwashed once
with ice-cold PBS and solubilized in lysis buffer for 2 h at 4 °C.
Then, lysates were clarified by centrifugation at 5,000 g for 20
min. 500 g of protein lysates was immunoprecipitated with
Myc or PED antibodies for 16 h. The precipitates were incu-
bated with protein G-Sepharose beads at 4 °C for 1 h with shak-
ing. Beads were precipitated by centrifugation at 1,000 g for 5
min at 4 °C and washed five times with ice-cold washing buffer.
After the final wash, the pellets were resuspended in 30l of 1
SDS electrophoresis buffer and heated to 95 °C for 5 min prior
to protein separation by 15% SDS-PAGE.Western blot analysis
was performed as described above.
Purification of Ubiquitin-PED/PEA-15 Conjugates—Cellular
ubiquitinylation assay was performed as described by Musti et
al. (29). Briefly, 24 h after transfection, cells expressing His-
tagged-PED/PEA-15 (PED/PEA-15Y1) and HA-ubiquitin were
harvested in 2ml of 6M guanidium-HCl, 0.1 MNa2HPO4/NaH2
PO4 (pH 8) plus 5 mM imidazole/100-mm dish and sonicated
with a Branson micro-tipped sonifier for 30 s to reduce viscos-
ity. Lysatesweremixed on a rotatorwith 0.2ml (settled volume)
of Ni2-nitrilotriacetic acid-agarose (Qiagen) for 4 h at room
temperature. The slurry was applied to a Bio-Rad Econo-Col-
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umn.The columnwas successivelywashedwith the following: 1
ml of 6 M guanidium-HCl, 0.1 MNa2HPO4, NaH2 PO4 (pH 8); 2
ml of 6 M guanidium-HCl, 0.1 MNa2HPO4, NaH2 PO4 (pH 5.8);
1 ml of 6 M guanidium-HCl, 0.1 M
Na2 HPO4, NaH2 PO4 (pH 8); 2 ml
of (6 M guanidium-HCl, 0.1 M Na2
HPO4, NaH2 PO4 (pH 8), protein
buffer) 1:1; 2 ml of (6 M guanidium-
HCl, 0.1 M Na2 HPO4, NaH2 PO4
(pH 8), protein buffer) 1:3; 2 ml of
protein buffer; 1ml of protein buffer
plus 10 mM imidazole. Elution was
performed with 1 ml of protein
buffer plus 200 mM imidazole. Pro-
tein buffer is 50 mM Na2 HPO4,
NaH2 PO4 (pH 8), 100 mMKCl, 20%
glycerol, and 0.2% Nonidet P-40.
The eluate was trichloroacetic acid-
precipitated for further analysis by
Western blot with HA antibody.
Cell Death Analysis by Flow
Cytometry—Cells were harvested
and suspended in the sample buffer
(PBS 2% fetal bovine serum; PBS
0.1% bovine serum albumin) and
washed and resuspended in 0.3 ml
of PBS. After adding 0.7 ml of cold
absolute ethanol, cells were fixed for
at least 2 h at20 °C, washed twice,
and resuspended in 0.4 ml of PBS.
Samples were then incubated with
20 l of propidium iodide (1 mg/ml
stock solution) and 2 l of RNaseA
(500 mg/ml stock solution) in dark
for 30 min at room temperature.
Samples were stored at 4 °C until
analyzed by flow cytometry.
RESULTS
Regulation of PED/PEA-15 Pro-
tein Expression by Phorbol Esters—
The expression of PED/PEA-15 is up-regulated by phorbol
myristate acetate (TPA) in the mouse skin upon experimental
carcinogenesis as well as in different human tumors (7–9, 15).
To investigate the molecular mechanisms regulating PED/
PEA-15 expression, HEK-293 cells, stably transfected with
PED/PEA-15 cDNA (293PEDY1), were incubated with serum-
free medium in the absence or in the presence of 1 M TPA.
Treatment of 293PEDY1 cells with TPA increased PED/PEA-15
levels in a time-dependentmanner (Fig. 1A). Serumdeprivation
alone was sufficient to reduce PED/PEA-15 protein levels by
3-fold (Fig. 1B). This decrease was totally reverted by the
simultaneous exposure to TPA. Pretreatment of the cells with
the protein synthesis inhibitor cycloheximide (40 g/ml)
reduced TPA effect by only 25% (Fig. 1B, left panel). Similar
results were also obtained by evaluating the levels of PED/
PEA-15 in C5N keratinocytes, expressing only the endogenous
compendium of the protein (Fig. 1B, right panel). Moreover, as
shown in Fig. 2, PED/PEA-15 mRNA was also increased in
untransfectedC5N cells following 6 and 20 h of TPA treatment.
Thus, TPA up-regulates PED/PEA-15 mRNA and protein
FIGURE 1. TPA effect on PED/PEA-15 protein expression. A, 293PEDY1 cells were serum-starved for 40 h and
stimulatedwith1MTPAforthe indicatedtimes.Cell lysateswereseparatedonSDS-PAGEandimmunoblottedwith
PEDAb. Filters have been analyzed by laser densitometry. The error bars represent themean S.D. of the densito-
metric analyses. B, 293PEDY1 cells (left panel) and C5N keratinocytes (right panel) were serum-starved, as indicated,
and treatedwith 1M TPA for 20 h in the absence or in the presence of 40g/ml cycloheximide (CXM). Cell lysates
were then analyzed by PED immunoblot, and the results were quantitated by laser densitometry. The autoradio-
graphs shown are representative of three (A) and four (B) independent experiments.
FIGURE 2. TPA effect on PED/PEA-15mRNA levels. The abundance of mRNAs
for PED/PEA-15 was determined by real-time RT-PCR analysis of total RNA iso-
lated fromC5Ncells following treatmentwith TPA (1M) for the indicated times,
using -actin as internal standard. The mRNA levels in TPA-stimulated cells are
relative to those in control cells. Each error bar represents themean S.D. of four
independentexperiments ineachofwhich reactionswereperformed in triplicate.
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expression. However, TPA regulation is, at least in part, inde-
pendent of protein synthesis.
Regulation of PED/PEA-15 Expression by Serine Phosphor-
ylation—It has been shown that PED/PEA-15 expression is
tightly regulated by its phosphorylation state (22).We therefore
investigated whether TPA could induce PED/PEA-15 phos-
phorylation. To this end, protein extracts of TPA-stimulated
293PEDY1 and C5N cells were immunoblotted with antibodies
against the phosphorylated forms of Ser-104 and Ser-116 (Fig.
3A). In 293PEDY1 cells, Ser-104 phosphorylation increased
within the initial 30 min of TPA exposure, declining thereafter.
At variance, Ser-116 phosphorylation was barely detectable at
30 min and progressively raised for up to 20 h after TPA expo-
sure. Similarly, inC5Nkeratinocytes, 20 h of TPA treatment led
to a significant increase of Ser-116 phosphorylation, with
almost undetectable changes of Ser-
104 phosphorylation (Fig. 3A).
To assess the relevance of those
phosphorylation sites, PED/PEA-15
mutants bearing Ser-104 3 Gly
(PEDS104G) or Ser-116 3 Gly
(PEDS116G) substitutions were
transfected in HEK293 cells. TPA
treatment increased the levels of the
wild-type PED/PEA-15 (PEDWT)
and of PEDS104G by about 4-fold. At
variance, PEDS116G expression was
increased by only 2-fold upon TPA
exposure (Fig. 3B), suggesting that
phosphorylation of Ser-116 is
required for TPA regulation of
PED/PEA-15 expression.
PKC Regulation of PED/PEA-15
Expression—To identify the kinase
responsible for the regulation of
PED/PEA-15 expression, 293PEDY1
cells were treated with specific
phosphorothioate antisense oligo-
nucleotides (ASO) toward individ-
ual PKC isoforms (Fig. 4). Based on
Western blot experiments, ASO for
PKC-, -, and - did not signifi-
cantly affect PED/PEA-15 expres-
sion levels when compared with
scrambled (SO) oligonucleotide
controls. The expression of the tar-
geted PKC isoform was selectively
reduced by50%, however. At vari-
ance, ASO-mediated silencing of
PKC- expression (PKC-ASO) was
accompanied by a significant 70%
decrease of PED/PEA-15 levels (Fig.
4). A scrambled oligonucleotide
(PKC-SO) did not induce any
detectable change (Fig. 4). A reduc-
tion of PED/PEA-15 expression was
also observed when 293PEDY1 cells
were transfected with a dominant-
negative (DN) PKC- mutant or with PKC-ASO and stimu-
lated with TPA for 20 h (Fig. 5A). CaMKII and Akt/PKB have
been shown to directly phosphorylate PED/PEA-15 at Ser-116
(22, 23). Interestingly, a 75% decrease of PED/PEA-15 expres-
sion was also detected in 293PEDY1 cells treated with the CaMK
inhibitor, KN-93 (Fig. 5A). Similarly, in C5N keratinocytes,
TPA-induced up-regulation of PED/PEA-15 protein expres-
sion was reduced by about 70% by KN-93 treatment (Fig. 5B).
Next, we investigated whether TPA could regulate CaMKII
activity in 293PEDY1 and in C5N cells. In this regard, CaMKII
phosphorylation (Fig. 6A) was induced by TPA and well corre-
lated with increased PED/PEA-15 expression levels and Ser-
116 phosphorylation in 293PEDY1 cells (Figs. 1A and 3A). Con-
sistently, 20 h of TPA treatment of C5N cells was accompanied
by a 2.5-fold increase ofCaMKII phosphorylation (Fig. 6A). The
FIGURE 3.Regulationof PED/PEA-15phosphorylation levels by TPA.A, 293PEDY1 andC5N cellswere serum-
starved and stimulated with 1 M TPA for the indicated times. Cell lysates were separated on SDS-PAGE and
immunoblotted either with p-PEDS104 Ab or with p-PEDS116 Ab. Each filter has been reprobed with PED Ab
for the normalization. The results have been analyzed by laser densitometry, and the error bars represent the
mean S.D. of the densitometric analyses obtained in four duplicate experiments. B, HEK293 cells have been
transfected with PEDWT, PEDS104G, and 293PEDS116G, as indicated. Next, cells were serum-starved and stimu-
latedwith 1MTPA for 20 h. Cell lysateswere separated on SDS-PAGE and immunoblottedwith PEDAb. Filters
have been analyzed by laser densitometry. The autoradiograph shown is representative of five independent
experiments. The error bars represent the mean S.D. of the densitometric analysis.
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expression of DN-PKC- and the treatment of 293PEDY1 cells
with PKC-ASO reduced by about 65% TPA-induced CaMKII
activation (Fig. 6B). Conversely, overexpression of the wild-
type PKC- led to3-fold increase of CaMKII activity. At vari-
ance, Akt/PKB activity was not induced following 20 h of TPA
treatment of both 293PEDY1 and C5N cells (Fig. 6C).
Moreover, TPA treatment and PKC- overexpression
increased by 5-fold the phosphorylation of PED/PEA-15 at
Ser-116. Pretreatment of 293PEDY1 cells with KN-93 almost
completely reverted both TPA- and PKC--induced phospho-
rylation of PED/PEA-15 (Fig. 7A). TPA-induced Ser-116 phos-
phorylation was also reduced by KN-93 in C5N keratinocytes.
Consistent results were obtained in transiently transfected
HEK293 cells by analyzing the expression of PEDWT and
PEDS104G but not of PEDS116G (Fig. 7B). Indeed, PKC--medi-
ated changes of PEDWT and PEDS104G were prevented by
KN-93, which, instead, had no effect on the regulation of
PEDS116G expression.
Regulation of PED/PEA-15 Ubiquitinylation—We hypothe-
sized that PED/PEA-15 protein accumulation within the cell
was due to decreased degradation. To investigate the mecha-
nisms regulating PED/PEA-15 degradation, 293PEDY1 cells
were treated with the proteasomal inhibitor lactacystin. Lacta-
cystin (30 M) inhibited the degradation of PED/PEA-15
induced by serum deprivation by 70% and almost completely
reverted the effect of the PKC-ASO (Fig. 8A). Lactacystin
treatment also prevented PED/PEA-15 degradation induced by
KN-93 in the 293PEDY1 cells (data not shown). In addition, lac-
tacystin, at variance with TPA, increased the expression of
PEDS116G at a similar extent as PEDWT (Fig. 8B), suggesting that
PED/PEA-15 phosphorylation at the Ser-116 was required to
escape degradation. Following lactacystin treatment of the
untransfected C5N cells, PED/PEA-15 protein levels were also
increased by 2.5- and 3-fold, respectively, in the absence or in
the presence of TPA (Fig. 8B). In both cases, the incubation
with KN-93 did not significantly reduce lactacystin effect on
PED/PEA-15 protein levels. Thus, CaMK block was overcome
by proteasome inhibitors.
These data were consistent with the hypothesis that PED/
PEA-15 is largely degraded within the proteasomal compart-
ment. Proteasome-targeted proteins are usually ubiquitiny-
lated (30). His-tagged PED/PEA-15 and HA-tagged ubiquitin
have been transfected, alone or in combination, in HEK293
cells, and PED/PEA-15-bound ubiquitin was detected byWest-
ern blot with HA antibodies (Fig. 9A). A typical smear was
observed in cells co-transfected with both constructs, indicat-
ing that PED/PEA-15 is a ubiquitinylated protein (Fig. 9A).
FIGURE 4. Regulation of PED/PEA-15 expression levels by PKC isoforms.
293PEDY1 cellswere treatedwithphosphorothioate antisense (ASO) and sense
(SO) oligonucleotides (3 g/ml) directed against PKC-, -, -, and -. Cell
lysates were then analyzed by PED immunoblot, and the results were quan-
titated by laser densitometry. The autoradiograph shown is representative of
five independent experiments. The error bars represent the mean  S.D. of
the densitometric analysis.
FIGURE 5. Regulation of PED/PEA-15 expression levels by PKC and
CaMK. 293PEDY1 (A) and C5N (B) cells were serum-starved and treated with 1
M TPA or with 10 M KN-93 for 20 h in the absence or in the presence of
PKC-ASO and PKC-SO or DN-PKC, as indicated. Cell lysates were then ana-
lyzedbyPKC- (upper part) or PEDAb (lower part) immunoblot, and the results
were quantitatedby laser densitometry. The autoradiographs shownare rep-
resentative of four (A) and three (B) independent experiments. The error bars
represent the mean S.D. of the densitometric analyses.
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Next, 293PEDY1 cells were incubated in serum-freemedium and
treated with TPA for 20 h or transfected with wild-type PKC-.
PED/PEA-15 immunoprecipitates were then blotted with FK1
antibodies, which recognize polyubiquitinylated proteins.
Interestingly, PED/PEA-15 ubiquitinylation was 2.5-fold
increased by serum starvation. At the opposite, it was reduced
by2-fold by TPA treatment and by overexpression of PKC-
(Fig. 9B). Both TPA and PKC- failed to decrease PED/PEA-15
ubiquitinylation in the presence of KN-93. Also, ubiquitinyla-
tion of the PEDS104G mutant was reduced in a manner compa-
rable with that of PEDWT, whereas that of the PEDS116Gmutant
did not significantly change (Fig. 9C).
Functional Relevance of Ser-116 Phosphorylation—To fur-
ther investigate the relevance of PED/PEA-15 phosphorylation
on its anti-apoptotic action, 293PEDY1 cells have been deprived
of serum for 20 h in the absence or in the presence of TPA (Fig.
10). As expected, TPA exposure largely rescued the cell death
induced by serum starvation. TPA effect was also mimicked by
PKC- overexpression in 293PEDY1 cells (Fig. 10A). However,
the incubation with KN-93 prevented both TPA and PKC-
FIGURE 6. TPA and PKC- effect on CaMKII phosphorylation. A, 293PEDY1
cells were serum-starved and treated with 1 M TPA for the indicated times.
Cell lysates were analyzed by p-CaMKII immunoblot. Filters were then rep-
robed with CaMKII Ab for normalization, and the results were quantitated by
laser densitometry. The autoradiograph shown is representative of five (for
293PEDY1) and three (for C5N) independent experiments. The error bars repre-
sent the mean  S.D. of the densitometric analysis. B, 293PEDY1 cells were
serum-starved and treated with 1 M TPA for 20 h in the absence or in the
presence of PKC-ASO or of wild-type or a dominant-negative PKC-mutant.
Cell lysates were then analyzed by immunoblot with p-CaMKII and CaMKII
Abs, and the results were quantitated by laser densitometry. The autoradio-
graph shown is representative of four independent experiments. The error
bars represent themean S.D. of the densitometric analysis. C, 293PEDY1 and
C5N cells were serum-starved and treated with 1 M TPA for 20 h. Akt/PKB
activity has beenmeasured as described previously (35). The error bars repre-
sent the mean S.D. of three independent experiments in triplicate.
FIGURE 7. Regulation of PED/PEA-15 phosphorylation and expression by
CaMKII. A, 293PEDY1 and C5N cells were serum-starved and treatedwith 1M
TPA for 20 h or transfectedwith a pcDNAIII plasmid containing a PKC- cDNA,
in the absence or in the presence of 10 M KN-93. Cell lysates were then
analyzedby immunoblotwithp-PEDS116andPEDAbs. The results havebeen
analyzed by laser densitometry, and the error bars represent themean S.D.
of the densitometric analyses obtained in four duplicate experiments.
B, HEK293 cells transfected with PEDWT, PEDS104G, and PEDS116G alone or in
combinationwith PKC- cDNA and further incubated in the absence or in the
presence of 10 M KN-93. Cell lysates were then analyzed by PKC- and PED
immunoblot, and the results were quantitated by laser densitometry. The
autoradiographs shownare representativeof four independent experiments.
The error bars represent the mean S.D. of the densitometric analyses.
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rescue of cell death, suggesting that CaMKII-induced phospho-
rylation of PED/PEA-15 at Ser-116 was required for this effect
(Fig. 10A). To further sustain this hypothesis, we have tested
TPA protection from cell death in HEK293 cells transfected
with either PEDWT or PEDS116G. Although normally inducing
survival of serum-starved cells transfected with PEDWT, TPA
effect was 2-fold reduced in cells overexpressing PEDS116G
(Fig. 10B).
DISCUSSION
Elevated expression of the anti-apoptotic protein PED/
PEA-15 has been found in transformed cell lines and confers
resistance to apoptotic stimuli (7–11, 15, 22). An increase of
PED/PEA-15 levels is also detected in the papillomatous skin of
dimethylbenzanthracene/TPA-treated mice upon experimen-
tal carcinogenesis protocols (15), further indicating that raised
PED/PEA-15 expressionmay play a role in cellular transforma-
tion. In this work, we have investi-
gated the molecular mechanisms
through which the tumor-promot-
ing agent TPA affects PED/PEA-15
expression. Two lines of evidence
indicate that, at least in part, PED/
PEA-15 expression is regulated by
TPA at the post-translational level.
Firstly, similar to previous observa-
tions in mouse skin and in keratino-
cyte cell lines (15), phorbol esters
up-regulate PED/PEA-15 protein
expression in HEK293 cells ectopi-
cally expressing the PED/PEA-15
cDNA under the transcriptional
control of the cytomegalovirus pro-
moter. In addition, in these cells, as
well as in untransfected keratino-
cytes, PED/PEA-15 regulation by
TPA also occurs in the presence of
the protein synthesis inhibitor
cycloheximide. The evidence that
TPA effect was partially reduced
by cycloheximide, however, sug-
gests that additional regulation
may occur at the transcriptional
level. Indeed, PED/PEA-15 mRNA
levels are also significantly
increased in untransfected C5N
cells following TPA stimulation.
Nonetheless, PED/PEA-15 phos-
phorylation is a major event for the
regulation of its stability (22). Here,
we show that Ser-116 is the key
phosphorylation site enabling TPA
regulation of PED/PEA-15 expres-
sion. We have previously described
that Ser-116 phosphorylation by
Akt/PKB increases PED/PEA-15
half-life following insulin stimula-
tion (22). It is unlikely that Akt/PKB
is involved in TPA control of PED/PEA-15 expression since
there is no sustainedAkt/PKB activation uponTPAexposure of
HEK293 cells and C5N keratinocytes. CaMKII is a more likely
candidate. Indeed, Kubes et al. (23) have reported that CaMKII
may also phosphorylate PED/PEA-15 at Ser-116 and, consist-
ent with findings in other cell types (31), we found that TPA
increases CaMKII activity in HEK293 and in C5N cells (Fig. 6).
In addition, the timing of CaMKII activation closely parallels
PED/PEA-15 phosphorylation at Ser-116 following TPA stim-
ulation. Finally, pharmacological inhibition of CaMKII with
KN-93 almost totally blocked TPA-induced Ser-116 phospho-
rylation. At variance, Ser-104 phosphorylation was rapidly
induced by TPA and then decreased upon prolonged incuba-
tion. Ser-104 is known to be directly phosphorylated by PKC
following endothelin-1 treatment of astrocytic cells (23). The
same occurs with TPA since the down-regulation of conven-
tional PKC isoforms after long termexposurewas accompanied
FIGURE 8. Effect of lactacystin on PED/PEA-15 expression. A, 293PEDY1 cells were treated with either PKC-
ASO or PKC-SO and further incubated in the absence or in the presence of 30 M lactacystin (Lact), as indi-
cated. Cell lysates were then analyzed by PED immunoblot, and the results were quantitated by laser densi-
tometry. The autoradiograph shown is representative of four independent experiments. The error bars
represent themean S.D. of the densitometric analysis. FCS, fetal calf serum. B, HEK293 cells transfected with
PEDWT or PEDS116G were treated with 1 M TPA or 30 M lactacystin for 20 h as indicated. C5N cells were
serum-starved and incubatedwith TPA (1mM), KN-93 (10mM), and lactacystin (30mM) as indicated. Cell lysates
were then analyzed by PED immunoblot, and the results were quantitated by laser densitometry. The autora-
diographs shown are representative of four (for HEK293) and three (for C5N) independent experiments. The
error bars represent the mean S.D. of the densitometric analyses.
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by a decline of Ser-104 phosphorylation. However, genetic
silencing of conventional and novel PKC isoforms, which are
canonical intracellular targets of TPA, further argued against
the involvement of Ser-104 phosphorylation by PKC in direct
regulation of PED/PEA-15 expression. Consistent with this, the
Ser-1043Gly mutant, but not the Ser-1163Gly mutant, was
equally sensitive to TPA action as the wild-type PED/PEA-15.
Altogether, these observations indicate that insulin and phor-
bol esters use different pathways to regulate PED/PEA-15 pro-
tein expression, both converging at the level of Ser-116 phos-
phorylation. For instance, whereas Akt/PKB is the major
candidate kinase for the insulin action (22), CaMKIImaymedi-
ate PED/PEA-15 phosphorylation at the Ser-116 in response to
TPA.The finding that LY294002 inhibition of phosphatidylino-
sitol 3-kinase activity also reduces TPA effect on PED/PEA-15
expression (data not shown)may be due to decreased activity of
other downstream molecules different from Akt/PKB.
Indeed, a pivotal role has emerged for PKC- in TPA regula-
tion of PED/PEA-15 expression. Both the antisense reduction
of PKC- and the expression of a
dominant-negative PKC- mutant
led to a decrease of TPA-regulated
PED/PEA-15 phosphorylation at
Ser-116, accompanied by a reduc-
tion of PED/PEA-15 protein levels.
This led us to hypothesize that
PKC- could either directly phos-
phorylate Ser-116 or directly affect
CaMKII activity. No PED/PEA-15
phosphorylation at Ser-116 was
induced in vitro by active recombi-
nant PKC- (data not shown). At
variance, inhibition of PKC-
expression and/or function in
HEK293 cells almost completely
abolished CaMKII induction by
TPA, supporting the hypothesis
that PKC- could affect PED/
PEA-15 expression by acting
upstream of CaMKII. Accordingly,
PKC--increased CaMKII activity
was paralleled by raised Ser-116
phosphorylation and PED/PEA-15
expression levels.Whether PKC- is
directly activated by phorbol esters
is still debated (32–34). Alterna-
tively, however, prolonged exposure
of the cell toTPA,which is known to
down-regulate conventional PKC
isoforms, may up-regulate PKC-
activity by removing the tonic inhib-
itory constraint exerted by the firsts
on the latter. This is consistent with
our previous observation, indicating
that PKC- hyperactivation causes
a downstream inhibition on PKC-
(24, 35).
Regulation of PED/PEA-15 phos-
phorylationmay be a common event, which contributes to pro-
tection from apoptosis, driven by either PKC- (36–38) or
CaMKII (39–41). Intriguingly, we have previously described
that PED/PEA-15 overexpression inhibits insulin induction of
PKC-, thereby impairing glucose uptake (24, 35). It is now
emerging that PKC- activation instead up-regulates PED/
PEA-15 protein levels, which in turn, may negatively affect
PKC- function. This is also in agreement with recent evidence
showing that forced expression of PKC- may inhibit insulin
and growth factor signaling (42–44).
Recently, Renganathan et al. (21) have proposed that PED/
PEA-15 phosphorylation at specific residues is important in
enabling its interaction with selected intracellular proteins. In
particular, phosphorylation at Ser-116 promotes its binding to
FADDand plays an important role in protecting cells from apo-
ptosis (9, 10, 21). Here, we show that Ser-116 phosphorylation
is also involved in preventing PED/PEA-15 degradation in the
26 S proteasome. Indeed, lactacystin treatment mimicked the
effect of TPA and prevented PED/PEA-15 protein loss follow-
FIGURE 9. Regulation of PED/PEA-15 ubiquitinylation. A, HEK293 cells were transfected with His-Myc-
PED/PEA-15 and HA-ubiquitin (HA-Ub) alone or in combination. Upon purification of His-Myc-PED/PEA-15
and separation on SDS-PAGE, filters were probedwith HAAb. The autoradiograph shown is representative
of five independent experiments. B, 293PEDY1 cells were serum-starved and treated with 1 M TPA for 20 h
or transfected with PKC- cDNA in the absence or in the presence of 10 M KN-93. Cell lysates were
separated on SDS-PAGE and immunoblotted with FK1 and PED Abs. The results have been analyzed by
laser densitometry, and the error bars represent the mean S.D. of the densitometric analyses obtained
in four duplicate experiments. FCS, fetal calf serum. C, HEK293 cells transfected with PEDWT, PEDS104G, and
PEDS116G were serum-starved and treatedwith 1M TPA for 20 h. Cell lysates were separated on SDS-PAGE
and immunoblotted with FK1 and PED Abs. The results have been analyzed by laser densitometry, and the
error bars represent the mean  S.D. of the densitometric analyses obtained in four duplicate
experiments.
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ing growth factor deprivation or PKC- silencing. Different
fromTPA, however, lactacystin also rescued the expression lev-
els of the non-phosphorylatable Ser-116 3 Gly mutant, indi-
cating that phosphorylation at this sitemay confer the ability to
escape proteasomal degradation. Proteasomal targeting and
degradation are typical features of ubiquitinylated proteins
(30). Sur and Ramos (45) have recently shown that vanishin, a
death effector domain protein with a high degree of homology
withPED/PEA-15, is ubiquitinylated.Wenowpresent evidence
that PED/PEA-15 directly binds ubiquitin. Treatment with
TPA as well as PKC- overexpression reduced the ubiquitiny-
lation of wild-type PED/PEA-15 but had no effect on the Ser-
116 phosphorylation-deficient mutant. Preserved ubiquitinyla-
tionwas also observed in the presence of KN-93, indicating that
CaMKII phosphorylation plays an important role in the regu-
lation of PED/PEA-15 expression by controlling its ubiquitiny-
lation state. Finally, both KN-93 and Ser-1163 Gly substitu-
tion reduced TPA anti-apoptotic action, suggesting that
CaMKII activation and PED/PEA-15 phosphorylation at Ser-
116 are relevant for this effect.
Thus, we have shown that phorbol esters up-regulate PED/
PEA-15 expression by controlling its proteasomal degradation.
PKC- and CaMKII activities are necessary to enable TPA-
dependent phosphorylation of PED/PEA-15 at Ser-116. This
phosphorylation prevents ubiquinylation and proteasomal tar-
geting and induce PED/PEA-15 intracellular accumulation,
thereby enhancing its anti-apoptotic action.
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